Poster Presentations

* Presenting Author

PP-TH-001 THE EFFECT OF HYDROGEN SULPHIDE ON PLATELET ACTION
N. J. Truss* (UK), F. Y. Ali, P. C. J. Armstrong, T. D. Warner

PP-TH-002 NITRIC OXIDE INHIBITS PLATELET AGGREGATION INDEPENDANTLY FROM FORMATION OF THROMBOXANE A2
N. J. Truss* (UK), P. C. J. Armstrong, S. K. Shinhmar, T. D. Warner

PP-TH-003 HOMOCYSTEINE INDUCES CHANGES IN PLATELET CALCIUM MOBILIZATION AND FUNCTION IN TYPE 2 DIABETES MELLITUS
N. Alexandru* (RO), I. Jardín, D. Popov, M. Simionecu, J. García- Estañ, G. M. Salido, J. A. Rosado

PP-TH-004 LOCAL DISTRIBUTION OF CYTOSOLIC CALCIUM ION IN PLATELET FORMING THROMBI ON COLLAGEN FIBRILS AND VON WILLEBRAND FACTOR UNDER CONTROLLED BLOOD FLOW CONDITION
N. Tamura* (JP), H. Ishida, S. Goto

PP-TH-005 SOLUBLE ELASTIN INHIBITS PLATELET ACTIVATION MEDIATED THROUGH GLYCOPROTEIN IB
O. Inoue* (JP), K. Suzuki-Inoue, Y. Ozaki

PP-TH-006 STUDY OF THE RESISTANCE IN ASPIRIN, BY DETERMINATION OF GLYCOPROTEIN ON THE PLATELET MEMBRANE
P. E. Makris* (GR), M. Moshou, M. P. Makris, G. Koliakos

PP-TH-007 INTEGRIN ALPHAIIBBETA3 OUTSIDE-IN SIGNALING VIA SYK INDUCES PLATELET PROCOAGULANT ACTIVITY
P. E. J. van der Meijden* (NL), M. A. H. Feijge, K. Gilio, K. Hamulyak, J. W. M. Heemskerk

PP-TH-008 CHARACTERIZATION OF PLATELET NITRIC OXIDE PRODUCTION TRIGGERED BY PLATELET ADHESION UNDER FLOW USING IMAGE SEQUENCE ANALYSIS
G. Guglielmini, M. Cozzi, M. Battiston, M. Mazzucato, P. Gresele* (IT), L. de Marco

PP-TH-009 THE DYNAMICS OF PLATELET ACTIVATION IN VIVO
P. L. Gross* (CA), R. Ni, B. Esposito, M. L. Rand, J. I. Weitz

PP-TH-010 IDENTIFICATION OF FIVE NOVEL 14-3-3 ISOFORMS INTERACTING WITH THE PLATELET GPIB-IX COMPLEX
P. Mangin* (FR), N. Receveur, V. Wurtz, C. Gachet, F. Lanza

PP-TH-011 MOLECULAR MECHANISMS UNDERLYING THE DIFFERENTIAL REGULATION OF PLATELET DENSE GRANULE SECRETION BY PROTEIN KINASE C-DELTA
R. Chari* (US), S. Kim, S. Murugappan, A. Sanjay, J. L. Daniel, S. P. Kunapuli

PP-TH-012 OUTSIDE-IN SIGNALING INDUCED BY THROMBOSPONDIN-1 ENHANCES THROMBUS FORMATION: INVOLVEMENT OF CD36
R. Nergiz-Ünal* (NL), M. J. E. Kuijpers, I. C. A. Munnix, J. F. Glatz, J. W. M. Heemskerk

PP-TH-013 SPECIFIC CYSTEINES IN THE EGF DOMAINS OF BETA3 AFFECT DIFFERENTLY ALPHAVBETA3 AND ALPHAIIBBETA3 RECEPTOR FUNCTION
R. Mor-Cohen* (IL), N. Rosenberg, U. Seligsohn

PP-TH-014 AKT REGULATES WEAK-AGONIST MEDIATED RAP1B ACTIVATION VIA A GSK-3 INDEPENDENT SIGNALLING PATHWAY IN PLATELETS
R. N. Sumathipala* (UK), K. V. Patel, S. Rahman, Y. Nishino, I. G. Webb, S. Rangarajan, W. J. Kaiser, J. M. Gibbins, Y. M. Patel

PP-TH-015 INTEGRIN-LINKED KINASE ASSOCIATED WITH INTEGRIN ACTIVATION
S. Honda* (JP), H. Shirotani-Ikejima, S. Tadokoro, Y. Maeda, T. Kinoshita, Y. Tomiyama, T. Miyata

PP-TH-016 ELECTRON MICROSCOPY CHARACTERIZATION OF PLATELET INTERACTION WITH CARBON NANOMATERIALS
S. H. Lacerda* (US), J. Semberova, O. Simakova, K. Holada, M. P. Gelderman, J. Simak

PP-TH-017 PLATELETS INTERACTION WITH PHOSPHOLIPASE A2 PURIFIED FROM THE AGKISTRODON BLOMHOFFII USSURIENSIS SNAKE VENOM
S. B. Otgontaij* (MN), E. E. Altantsetseg

PP-TH-018 GPIB ALPHA IS A COFACTOR BINDING THROMBIN AND THUS FACILITATING PAR1 CLEAVAGE
L. Faxälv, S. Nylander, R. Chaireti, F. Pettersson, T. L. Lindahl* (SE)

PP-TH-019 FRACTALKINE DESENSITIZES PLATELETS TO PLATELET INHIBITION BY THE ENDOGENOUS PLATELET INHIBITOR PROSTACYCLIN
U. Flierl* (DE), J. Bauersachs, A. Schaefer

PP-TH-020 NITRIC-OXIDE MEDIATED INHIBITION OF PLATELET FUNCTION IS REVERSED BY THROMBOSPONDIN-1
W. Roberts* (UK), R. Riba, K. M. Naseem

PP-TH-021 CD148 ENHANCES PLATELET RESPONSIVENESS TO COLLAGEN AND FIBRINOGEN BY MODULATING SRC FAMILY KINASE ACTIVITY
S. Ellison, A. Barr, M. G. Tomlinson, J. Zhu, A. Weiss, S. P. Watson, Y. A. Senis* (UK)

PP-TH-022 BF0801, A NOVEL PLATELET PHOSPHODIESTERASE INHIBITOR
S. Zhang, Y. Zhang, X. Yu, K. Bhavaraju, L. Hu, J. Jin, H. Du, S. P. Kunapuli, Z. Ding* (CN)

PP-TH-023 HEAT SHOCK IN VITRO MODEL: POSSIBLE RELATIONSHIP WITH PLATELETS MORPHOLOGY LYMPHOCYTES AND NEUTROPHILS LEUKOCYTES CHROMATIN REALIGNMENT
N. G. Kruchynsky* (BY), S. Vishnevskaya

PP-TH-024 PLATELET AGGREGATION AND SECRETION MEDIATED BY GPVI ACTIVATION ARE NOT ACCOMPANIED WITH INCREASE OF TISSUE FACTOR-DEPENDENT PROCOAGULANT ACTIVITY (PCA)
O. Panes* (CL), V. Matus, J. Pereira, D. Mezzano

PP-TH-025 THE P2Y1, P2Y12, GPIIB AND GPIIIA GENE EXPRESSIONS IN PLATELETS OF HEALTHY DONORS AND PATIENTS WITH MYOCARDIAL INFARCTION
O. V. Sirotkina* (RU), N. A. Bogankova, A. L. Schwarzman, T. V. Vavilova

PP-TH-026 PLATELET REACTIVITY IN DIFFERENT ETHNICITIES AND GENDER (PRIDE G) PILOT TRIAL
O. Bailon* (US), A. Singla, M. Antonino, J. Dichiara, K. Bliden, M. Hamed, T. Suarez, P. A. Gurbel, L. Lawal, U. S. Tantry

PP-TH-027 ADP-MEDIATED AGGREGATION AS A PHARMACODYNAMIC ASSAY UNDERESTIMATES THE ANTITHROMBOTIC ACTIVITY OF ELINOGREL, A COMPETITIVE, REVERSIBLE P2Y12 INHIBITOR, RELATIVE TO CLOPIDOGREL
P. B. Conley* (US), P. Andre, G. Stephens, H. Haberstock-Debic, M. Jurek, D. Gretler, D. R. Phillips

PP-TH-028 CALPAIN CLEAVES ANTI-APOPTOTIC PROTEINS IN ACTIVATED PLATELETS
P. A. Cordell* (UK), P. J. Grant, R. J. Pease

PP-TH-029 PLATELET AGGREGATION INHIBITOR FROM AGKISTRODON BLOMHOFFII USSURIENSIS VENOM
P. Dashnyam* (MN), B. Jugder, A. Nemekh

PP-TH-030 REVERSIBLE BINDING OF CANGRELOR TO THE P2Y12 RECEPTOR PREVENTS THE BINDING OF CLOPIDOGREL AND PRASUGREL ACTIVE METABOLITES
R. J. Buckland, H. M. Judge, A. Sugidachi, J. A. Jakubowski, R. F. Storey* (UK)

PP-TH-031 SYSTEMATIC IDENTIFICATION AND INTERPRETATION OF PLATELET PROTEIN LOCALISATION
R. G. Stanley* (UK), B. Wright, W. J. Kaiser, J. M. Gibbins

PP-TH-032 PALMITOYLATION SUPPORTS THE ASSOCIATION OF TETRASPANIN CD63 WITH CD9 AND WITH THE ACTIN CYTOSKELETON IN THROMBIN-ACTIVATED PLATELETS
S. J. Israels* (CA), E. M. McMillan-Ward

PP-TH-033 ALTERATIONS IN THE EXTERNAL REDOX POTENTIAL OF THE PLATELET ENVIRONMENT IMPACTS ON PLATELET REACTIVITY
S. O Neill* (IE), D. Murphy

PP-TH-034 MARKERS OF HUMAN PLATELET ACTIVATION IN HYPERHOMOCYSTEINAEMIC STATES
S. O Neill* (IE), S. A. McGarrigle, N. Moran, I. G. Graham, M. T. Cooney, A. Monavari, P. Mayne, P. B. Collins

PP-TH-035 DIMERIC-SPECIFIC CONFORMATION OF THE COLLAGEN-RECEPTOR GLYCOPROTEIN (GP) VI CONTAINS THE COLLAGEN-BINDING SITE OF NATIVE PLATELETS: DIRECT EVIDENCE PROVIDED BY A RECOMBINANT FAB SPECIFIC FOR DIMERIC GPVI
S. M. Jung* (JP), M. Moroi

PP-TH-036 USE OF MEMBRANE-PERMEABLE ITAM-PEPTIDES TO INVESTIGATE THE INITIAL REACTIONS OF PLATELET ACTIVATION INDUCED THROUGH THE PLATELET COLLAGEN RECEPTOR GLYCOPROTEIN (GP) VI
S. M. Jung* (JP), M. Moroi

PP-TH-037 APOLIPOPROTEIN E RECEPTOR 2 IS A PLATELET RECEPTOR FOR COAGULATION FACTOR XI
T. C. White-Adams* (US), M. A. Berny, E. I. Tucker, J. Pang, D. Gailani, R. T. Urbanus, P. G. de Groot, A. Gruber, O. J. T. McCarty

PP-TH-038 ENDOTHELIAL CELL SPECIFIC ADHESION MOLECULE (ESAM) LOCALIZES TO CELLCELL JUNCTIONS VIA A HOMOPHILIC INTERACTION BETWEEN ADJACENT CELLS, INDEPENDENT OF ITS C-TERMINAL PDZ-DOMAIN BINDING MOTIF
T. J. Stalker* (US), J. Wu, M. S. Chatterjee, S. L. Diamond, L. F. Brass

PP-TH-039 FIBRINOLYTIC CROSSS-TALK: PLATELET-BOUND PLASMINOGEN IS ACTIVATED BY MONOCYTE UPA
T. de Jouvencel* (FR), L. Doeuvre, L. Plawinski, R. Lijnen, E. Angles-Cano

PP-TH-040 DIFFERENTIAL ACTIVATION AND FUNCTIONAL ROLE OF MYOSIN LIGHT CHAIN (THR)18 AND (SER)19 PHOSPHORYLATIONS IN PLATELETS
T. M. Getz* (US), C. C. D. Dangelmaier, J. J. D. Daniel, S. S. P. K. Kunapuli

PP-TH-041 BIOCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF ASP1645, A NOVEL SELECTIVE P2Y12 RECEPTOR ANTAGONIST
T. Uemura* (JP), T. Kawasaki, Y. Moritani, C. Sakata, F. Takamura, J. Takasaki, Y. Koga, H. Ito, S. Mutoh

PP-TH-042 THE ANTIPLATELET EFFECT OF ASP1645, A NOVEL P2Y12 RECEPTOR ANTAGONIST, COMPARED WITH CLOPIDOGREL
T. Uemura* (JP), T. Kawasaki, C. Sakata, T. Shigenaga, Y. Moritani, J. Takasaki, Y. Koga, H. Ito, S. Mutoh

PP-TH-043 HUMAN PLATELETS EXPRESS MRNA AND SYNTHESIZE UPAR, BUT NOT UPA
V. Matus* (CL), O. Panes, E. Torres, C. G. Sáez, J. Pereira, D. Mezzano

PP-TH-044 ABSOLUTE QUANTITATION OF VWF MRNA FROM HUMAN NORMAL PLATELETS
V. A. Zapata* (AR), A. C. Kempfer, M. A. Carrivale, J. H. Paiva Palomino, A. Vellicce, Y. P. Powazniak, M. A. Lazzari

PP-TH-045 BINDING OF PLATELET GLYCOPROTEIN IB-BETA THROUGH THE CONVEX SURFACE OF LEUCINE-RICH REPEATS DOMAIN OF GLYCOPROTEIN IX
X. Mo* (US), N. X. Nguyen, P. A. McEwan, X. Zheng, J. A. López, J. Emsley, R. Li

PP-TH-046 AN IN VITRO MODEL TO VISUALIZE AND QUANTIFY PHAGOCYTOSIS OF PLATELETS AND VWF
Y. P. Wu* (NL), D. E. van der Wal, P. G. de Groot, J. W. N. Akkerman

PP-TH-047 SEROTONIN IMPROVES CLOT FORMATION AND VISCOELASTIC PROPERTIES
A. M. Galan* (ES), I. Lopez-Vilchez, F. Navalon, M. Pino, C. Gasto, G. Escolar

PP-TH-048 HUMAN BLOOD PLATELET FUNCTION AND PROTEOME FOLLOWING CHRONIC INTAKE OF ORANGE JUICE
A. Della Corte, S. Marcone, M. Crescente, L. Giordano, W. Coletta, C. Tamburrelli, M. Barisciano, A. de Curtis, L. Iacoviello, R. Lorenzet, G. de Gaetano, M. B. Donati, C. Cerletti* (IT), D. Rotilio

PP-TH-049 A HIGH THROUGHPUT STUDY OF PLATELET CALCIUM RESPONSE TO PAIRWISE COMBINATION FROM A 6-DIMENSIONAL AGONIST SPACE ALLOWS TRAINING OF A SYSTEMS BIOLOGY NEURAL NETWORK “PLATELET BARCODE”
M. S. Chatterjee* (US), J. E. Purvis, S. L. Diamond

PP-TH-050 INHERITED HUMAN NOX2 DEFICIENCY IS ASSOCIATED WITH IMPAIRED ISOPROSTANE FORMATION AND REDUCED PLATELET RECRUITMENT
P. Pignatelli* (IT), R. Carnevale, S. di Santo, S. Bartimoccia, V. Sanguigni, A. Plebani, S. Basili, F. Violi

PP-TH-051 CLOCK REGULATES CIRCADIAN PLATELET ACTIVITY
S. Horie* (JP), N. Ohkura, Y. Sudo, H. Hayashi, K. Shikata, N. Ishida, J. Matsuda, K. Oishi

PP-TH-052 BLOOD VOLUME IS SIGNIFICANTLY REDUCED IN A NOVEL PARALLEL PLATE FLOW CHAMBER
S. O’Brien* (IE), N. Kent, A. J. Ricco, D. Kenny, G. Meade

PP-TH-053 CAPTURE AND ASSAY OF INDIVIDUAL ADHERING PLATELETS
S. Ramstrom* (IE), L. Basabe-Desmonts, A. Lopez-Alonso, A. J. Ricco, J. O’Donnell, D. Kenny

PP-TH-054 THE CHS-4 CHROMATIN INSULATOR SEQUENCE PROTECTS CLONAL DOMINANCE OF HEMATOPOIETIC STEM CELLS TRANSDUCED WITH A SELF-INACTIVATING SIV VECTOR IN PLATELET-DIRECTED GENE THERAPY
T. Ohmori* (JP), S. Madoiwa, Y. Kashiwakura, A. Ishiwata, E. Akiba, M. Hasegawa, J. Mimuro, Y. Sakata

PP-TH-055 DEVELOPMENT OF A MODEL TO STUDY PLATELET FUNCTION UNDER CONDITIONS OF FLOW
V. X. Du* (NL), H. F. G. Heijnen, P. G. de Groot, A. Barendracht, M. Roest

PP-TH-056 FC GAMMA RIIA AND ALPHAIIB BETA3 SYNERGY IN PLATELET ADHESION TO IMMUNOGLOBULIN G
M. P. Brennan* (IE), M. Thai Trung King, S. Kerrigan, D. Cox

PP-TH-057 PLASMA LEVELS OF PLATELET-DERIVED MICROPARTICLES (PDMP) MIGHT COMPRISE A USEFUL INDICATOR FOR ANTIPLATELET THERAPY IN ANTIPHOSPHOLIPID SYNDROME (APS)
M. Yamazaki* (JP), Y. Kadohira, M. Maekawa, T. Hayashi, E. Morishita, H. Asakura, S. Nakao

PP-TH-058 P-CRESOL INHIBITS PLATELET AGGREGATION AND INDUCES ENDOTHELIAL CELL IL-8 PRODUCTION
M. C. Chang* (TW), J. H. Jeng

PP-TH-059 EFFECT OF SOLUBLE CD40L ON THE ACTIVITY OF MATRIXMETALLOPROTEINASE 9 OF MEG-01 CELLS
N. Butta* (ES), E. Arias-Salgado, M. Alvarez, M. Martin, I. Fernandez, V. Jimenez-Yuste, F. Hernandez

PP-TH-060 PLATELET AGGREGATION AND COAGULATION DISORDERS IN EHLERS-DANLOS SYNDROME
P. Martinez* (AR), P. Martinez, H. Caferri, M. Facchini, P. Iommi, E. Agriello, M. Brandt, S. Garbiero, L. Roumeque, D. di Paolo

PP-TH-061 RACIAL DIFFERENCES IN THROMBOTIC STATUS MAY EXPLAIN THE INCREASED INCIDENCE OF HAEMORRHAGIC STROKE IN JAPAN
S. Saraf, H. Ishii, J. Yamamoto, Y. Yamori, D. Gorog, S. Sharma* (UK)

PP-TH-062 VALIDATION OF RAPID AND AUTOMATED METHOD FOR MEASUREMENT OF ADAMTS-13 ACTIVITY AND AUTO ANTIBODIES
T. M. Owaidah, M. Ahmed* (SA), R. Al Nounou, N. Rasheed

PP-TH-063 ALTERATIONS OF PLATELET FUNCTION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
V. Popov* (RO), H. Bumbea, A. Vladareanu, C. Saftoiu, S. Radesi, A. Nicolescu, T. Savopol, E. Kovacs

PP-TH-064 INFLAMMATORY MODULATION OF MEGAKARYOCYTES AND THROMBOPOIESIS THROUGH TLR2 AND IL1R
L. M. Beaulieu* (US), E. Lin, N. Mavrogiorgos, R. Ingalls, J. E. Freedman

PP-TH-065 THE EFFECT OF IMMUNE THROMBOCYTOPENIC PURPURA (ITP) PLASMA ON MEGAKARYOCYTOPOIESIS IN VITRO: COMPARISON OF PRE VERSUS POST DIAGNOSIS PLASMA
M. Chang* (US), P. A. Nakagawa, S. A. Williams, K. L. Imfeld, J. S. Buzby, D. J. Nugent

PP-TH-066 NPLATE EXPANDS AND DIFFERENTIATES MEGAKARYOCYTIC CELLS IN UMBILICAL CORD BLOOD CULTURES
M. Chang* (US), P. A. Nakagawa, J. S. Buzby, D. J. Nugent

PP-TH-067 MICRORNA EXPRESSION SIGNATURES ARE DIFFERENT IN HUMAN NEONATAL COMPARED TO ADULT MEGAKARYOCYTES
R. K. Gutti* (US), H. Sallmon, M. Bailey, Z. Liu, M. C. Sola-Visner

PP-TH-068 EFFECT OF BLOOD CLOTS ON THE MEGAKARYOCYTIC POTENTIAL OF THAWED CORD BLOOD UNITS
S. Juutistenaho* Finland, S. Möttönen, M. Eskola, K. Aranko, R. Kekomäki

PP-TH-069 HIGH GLUCOSE CONCENTRATIONS RAPIDLY UPREGULATE CYCLOOXYGENASE-2 (COX-2) EXPRESSION IN HUMAN MEGAKARYOCYTES (MK)
T. Corazzi* (IT), P. Gresele, L. Bury, G. B. Bolli

PP-TH-070 HEMATOPOIETIC STEM CELL STIMULATORS THROMBOPOIETIN , ARP AND FIBRONECTIN PROVIDE A NOVEL STRATEGY FOR EXPANSION OF EARLY HEMATOPOIETIC AND MEGAKARYOCYTE-PROGENITOR CELLS FROM CORD BLOOD
V. R. Deutsch* (IL), E. Hubel, S. Kay, T. Ohayon, B. Katz, E. Naparstek, D. Grisaru

PP-TH-071 APOPTOTIC PROCESS IS INVOLVED IN THE EARLY PHASE OF MEGAKARYOPOIESIS, BUT NOT IN PLATELET PRODUCTION FROM MEGAKARYOCYTES
Y. Kozuma* (JP), H. Ninomiya, T. Kono, H. Y. Mukai, H. Kojima

PP-TH-072 GSK-3? NEGATIVELY REGULATES THROMBOPOIESIS IN AN IN VITRO NORMAL HUMAN CD34-POSITIVE CELL-DERIVED DIFFERENTIATION SYSTEM
M. Ono, Y. Matsubara* (JP), T. Shibano, Y. Ikeda, M. Murata

PP-TH-073 THROMBOPOIETIN STIMULATES THE CYTOPLASMIC MATURATION OF LOW-PLOIDY NEONATAL MEGAKARYOCYTES THROUGH THE MTOR PATHWAY
Z. Liu* (US), M. Bailley, R. Gutti, H. Sallmon, M. Sola-Visner

PP-TH-074 GLANZMANN THROMBASTHENIA (GT): A SERIES OF 12 GENETIC VARIANTS - 11 NOVEL- IN ITGB3 AND ITGA2B GENES IN 16 INDIVIDUALS FROM FRANCE AND GERMANY
B. Saposnik, M. Simansour, S. Binard, M. Hurtaud-Roux, V. Proulle, M. Gerard-Blanluet, D. de Prost, A. Nurden, U. Nowak Göttl And, N. Schlegel* (FR)

PP-TH-075 STRUCTURAL ANALYSIS OF THE HUMAN PLATELET ANTIGENS
N. Rosenberg* (IL), M. Landau

PP-TH-076 ESTIMATION OF INCIDENCE OF THROMBOCYTOSIS-INDUCED BY HEPARIN IN 1861 MEDICAL PATIENTS
M. Epinat, N. Moulin, E. Presles, T. Monatte, C. Guy, S. Laporte, P. Mismetti* (FR)

PP-TH-077 RITUXIMAB FOR REFRACTORY AND RELAPSING THROMBOTIC THROMBOCYTOPENIC PURPURA
P. N. Knoebl* (AT), P. Distelmaier, S. Koder, P. Schellongowski, P. Quehenberger

PP-TH-078 DECREASED EXPRESSION OF MBD2 AND MBD4 GENE AND GENOMIC-WIDE HYPOMETHYLATION IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA
Z. Chen, D. Gu, X. Chen, Z. Zhou, Z. Guo, J. Ge, H. Zhao, R. Yang* (CN)

PP-TH-079 CONGENITAL OR ACQUIRED ADAMTS13 DEFICIENCY OR BOTH – THAT’S THE QUESTION
S. C. Meyer* (CH), I. Sulzer, G. Mäder, J. N. George, B. Lämmle, J. A. Kremer Hovinga

PP-TH-080 HETEROZYGOUS ADAMTS13 MUTATIONS IN IDIOPATHIC TTP WITH SEVERE ACQUIRED ADAMTS13 DEFICIENCY
S. C. Meyer* (CH), S. Jin, W. Cao, W. Pos, J. Voorberg, X. L. Zheng, B. Lämmle, J. A. Kremer Hovinga

PP-TH-081 A HETEROZYGOUS ITGA2B R995W MUTATION CAUSES CONSTITUTIVE ACTIVATION OF THE ? IIB?3 RECEPTOR AND RESULTS IN CONGENITAL MACROTHROMBOCYTOPENIA
S. Kunishima* (JP), H. Kashiwagi, Y. Ito, Y. Fujimori, Y. Miyajima, Y. Takamatsu, J. Suzumiya, Y. Tomiyama, H. Saito

PP-TH-082 A NOVEL CASE OF SELECTIVE ENZYMATIC DEFECT OF CYCLOOXYGENASE-1 ASSOCIATED WITH HAEMORRHAGIC DIATHESIS
S. Pascale* (IT), A. Dragani, D. Mattoscio, E. Ferrante, L. Mucci, I. di Marzio, G. Davì, B. Rocca

PP-TH-083 CLINICAL MANIFESTATIONS OF DISORDERS ASSOCIATED WITH MYH9 MUTATIONS
S. Rittich* (CZ), D. Provaznikova, V. Geierova, D. Mikulenkova, I. Hrachovinova, P. Salaj

PP-TH-084 A NOVEL MUTATION OF A HIGHLY CONSERVED RESIDUE ASN2ASP OF INTEGRIN ALPHA-IIB CAUSES GLANZMANN THROMBASTHENIA
W. Mansour* (IL), N. Rosenbreg, H. Haushner, A. Koren, U. Seligsohn

PP-TH-085 FORMATION OF METHIONINE-SULFOXIDE AT POSITION 1606 OF VON WILLEBRAND FACTOR INHIBITS CLEAVAGE BY ADAMTS-13 WITHOUT AFFECTING PLATELET INTERACTION: A NEW PROTHROMBOTIC MECHANISM PROMOTED BY OXIDATIVE STRESS
R. de Cristofaro* (IT), S. Lancellotti, V. de Filippis, N. Pozzi, F. Peyvandi, R. Palla, B. Rocca, S. Rutella, P. Mannucci

PP-TH-086 RENAL THROMBOTIC MICROANGIOPATHY WITH SEVERE ARTERIAL NECROSIS IN A SEPTIC PORCINE 2-HIT MODEL
C. L. Bockmeyer, K. Kentouche, P. Reuken, S. Krause, C. Krusche, G. Marx, W. Losche, J. Becker, R. A. Claus* (DE)

PP-TH-087 DIFFERENTIAL TRANSCRIPTION OF MRNA CODING THE VWF-CLEAVING PROTEASE ADAMTS13 UNDER PROINFLAMMATORY STIMULATION IN ENDOTHELIAL AND STELLATE CELLS
R. A. Claus* (DE), F. Conradi, C. L. Bockmeyer, K. Kentouche, M. W. Sieber, P. Recknagel, W. Losche, S. Friedman, M. Bauer

PP-TH-088 EIGHT NOVEL ADAMTS13 MISSENSE MUTATIONS IN CHILDHOOD AND ADULT ONSET CONGENITAL TTP
R. S. Camilleri* (UK), I. J. Mackie, R. Liesner, W. J. Chen, K. Manns, S. J. Machin, M. Scully

PP-TH-089 ADAMTS13 METALLOPROTEASE DOMAIN SUBSITES CONTROL CLEAVAGE SITE SPECIFICITY
R. de Groot* (UK), D. A. Lane, J. T. B. Crawley

PP-TH-090 IDENTIFICATION OF A FUNCTIONAL EXOSITE IN THE ADAMTS13 DISINTEGRIN-LIKE DOMAIN
R. de Groot* (UK), N. Ramroop, A. Bardhan, J. T. B. Crawley, D. A. Lane

PP-TH-091 IN VIVO ABSENCE OF ADAMTS13 DOES NOT ABROGATE VWF SIZE HETEROGENEITY
S. F. de Meyer* (BE), U. Budde, H. Deckmyn, K. Vanhoorelbeke

PP-TH-092 HYPOCHLOROUS ACID INACTIVATES ADAMTS13: AN OXIDATIVE MECHANISM FOR REGULATING ADAMTS13 ACTIVITY DURING INFLAMMATION
X. Fu* (US), Y. Wang, J. Chen, M. Ling, J. D. Kulman, J. A. López, D. W. Chung

PP-TH-093 ESTIMATION OF THE ADAMTS13 ACTIVITY IN PLASMA UNDER SHEAR STRESS USING NOVEL MONOCLONAL ANTIBODIES TO VWF
Z. Ma* (CN), N. Dong, J. Zhang, A. Wang, C. Ruan

 

PP-TH-094 GALLIC ACID COMPETES WITH ASPIRIN, RESVERATROL AND QUERCETIN FOR PLATELET COX-1: FUNCTIONAL AND MOLECULAR MODELLING STUDIES
M. Crescente, S. Momi, G. Jessen, M. Leone, H. D. Höltje, P. Gresele, C. Cerletti* (IT), G. de Gaetano

PP-TH-095 ANTI-DIABETIC SMALL MOLECULE 1,2,3,4,6-PENTA-<I>O</I>-GALLOYL-?-DGLUCOPYRANOSE INHIBITS PLATELET ACTIVATION BY PREVENTING GI?2MEDIATED SIGNAL TRANSDUCTION
H. Akbar* (US), K. Funk, S. Wulf, R. Perveen, Y. Cao, X. Chen

PP-TH-096 THROMBOXANE A2 RECEPTOR ANTAGONISM BY FLAVONOIDS: STRUCTUREACTIVITY RELATIONSHIPS
L. Navarro-Núñez* (ES), J. Castillo, M. Lozano, C. Martínez, O. Benavente-García, V. Vicente, J. Rivera

PP-TH-097 PLATELET AGGREGATION REVERSAL BY GPIIB-IIIA ANTAGONISTS: DEPENDENCE UPON AGONIST AND AGGREGATE AGE
H. E. Speich, A. D. Earhart, S. N. Hill, T. J. Kueter, M. M. White, L. K. Jennings* (US)

PP-TH-098 ANTIPLATELET EFFECTS OF PARTHENOLIDE, THE SESQUITERPENE LACTONE FROM FEVERFEW (THANACETUM PARTHENIUM
M. Helinska* (PL), M. Rozalski, B. Rychlik, C. Watala

PP-TH-099 ARONIA MELANOCARPA EXTRACT MAY LEAD TO PLATELET ACTIVATION WHEN USED AT HIGH CONCENTRATIONS
J. Golanski, M. Helinska* (PL), M. Rozalski, £. Kraszula, C. Watala

PP-TH-100 AN “IN VITRO” STUDY ABOUT THE COMBINED ANTIPLATELET EFFECTS OF CILOSTAZOL AND ASPIRIN
M. F. Alberto* (AR), S. Meschengieser, P. Pieczanski, J. Rodriguez Moncalvo, M. A. Lazzari

PP-TH-101 ANTIPLATELET EFFECTS OF ASPIRIN WITH PHYTOSTEROLS: COMPARISON WITH NON-ENTERIC COATED ASPIRIN ALONE
M. J. Antonino* (US), R. Coppolecchia, E. Mahla, K. P. Bliden, U. S. Tantry, P. A. Gurbel

PP-TH-102 DEVELOPMENT OF FC-GAMMA-RIIA ANTAGONIST
M. Thai Trung King* (IE), M. Adamo, M. Brennan, D. Cox

PP-TH-103 EV-077-3201-2TBS, A REVERSIBLE DUAL THROMBOXANE RECEPTOR ANTAGONIST AND THROMBOXANE SYNTHASE INHIBITOR, IS MORE POTENT THAN ASPIRIN IN INHIBITING ARACHIDONIC ACID AND COLLAGEN-INDUCED HUMAN PLATELET AGGREGATION IN VITRO
P. Alberts* (CH), P. Fontana, K. S. Sakariassen, H. Bounameaux, J. P. Meyer, A. Santana Sorensen

PP-TH-104 THE REVERSIBLY BINDING P2Y<SUB>12</SUB> RECEPTOR ANTAGONIST TICAGRELOR REDUCES EFFECT OF NEWLY FORMED PLATELETS UNDER LAMINAR FLOW CONDITIONS
R. Megens* (NL), M. Oude Egbrink, E. Nikookhesal, J. Heemskerk, J. J. J. van Giezen

PP-TH-105 INTEGRIN PRIMING DYNAMICS
R. R. Hantgan* (US), M. C. Stahle

 

PP-TH-106 A PRAGMATIC APPROACH FOR THE MEASUREMENT OF THE INR IN LIVER PATIENTS
A. F. Riddell* (UK), V. Calvaruso, E. G. Tuddenham, A. Burroughs, A. Gatt

PP-TH-107 THE EFFECT OF PLASMA-DILUTION ON THROMBIN GENERATION
E. de Smedt* (NL), R. Wagenvoord, C. Hemker

PP-TH-108 CODING AND PROMOTER REGION POLYMORPHISMS OF FACTOR VII (FVII) GENE IN ASIAN INDIANS VIS-À-VIS OTHER POPULATIONS OF THE WORLD: ALLELE FREQUENCIES, LINKAGE DISEQUILIBRIUM, FVII COAGULANT ACTIVITY (FVII:C) AND CORONARY ARTERY DISEASE (CAD)
M. S. Mukherjee* (IN), C. S. Deshpande, S. S. Joshi, K. R. Shetty

PP-TH-109 REGULATION OF TISSUE FACTOR-INITIATED THROMBIN GENERATION IN PLASMA BY FACTOR VII AND ACTIVATED FACTOR VII
M. V. Ovanesov* (US), T. K. Lee

PP-TH-110 TISSUE FACTOR AND GULF WAR-ASSOCIATED CHRONIC COAGULOPATHIES
R. R. Bach* (US), B. C. S. Slater

PP-TH-111 HAEMOSTATIC PROFILE AND DETERMINANTS OF RHEOLOGY IN NIGERIAN PREECLAMPTICS
R. A. Anyanwu* (NG), O. A. Awodu, A. B. Ande

PP-TH-112 OBSERVATION ON TISSUE FACTOR EXPRESSION OF MONOCYTES IN PATIENTS WITH ACUTE CEREBROCARDIAC THROMBOTIC DISEASES
R. Wang* (CN), L. Li, B. Z. Wen, D. Zhong, Y. T. Ma, P. Pen

PP-TH-113 COMPUTER MODELISATION OF THE PROTHROMBIN TIME TEST. CONCEPTION, VALIDATION AND POTENTIAL OF APPLICATION
S. Kerdelo* (FR), P. Redou, J. Tisseau, J. Abgrall

PP-TH-114 EFFECT OF PUERARIN ON THE EXPRESSION OF TISSUE FACTOR INDUCED BY ANGIOTENSIN II AND ITS MECHANISM IN VASCULAR ENDOTHELIAL CELLS
S. He* (CN), H. Wang, J. Hu, X. Shen, X. He, Z. Wen

PP-TH-115 FACTOR VIIa-ANTITHROMBIN COMPLEXES DURING CARDIOPULMONARY BYPASS SURGERY
S. J. Davidson* (UK), B. J. Woodhams

PP-TH-116 CANINE TISSUE FACTOR (TF) BINDS HUMAN AND CANINE FVII WITH SIMILAR HIGH AFFINITY WHICH CONTRASTS THE LOW AFFINITY FOR BINDING OF HUMAN TF TO CANINE FVII
T. Knudsen* (DK), B. B. Sørensen, H. R. Stennicke, L. C. Petersen, A. T. Kristensen

PP-TH-117 TISSUE FACTOR INDUCES PROMMP9 RELEASE AND ACTIVATES PROMMP2 IN OSTEOSARCOMA
T. Stokol* (US), J. L. Daddona, V. Rathnam

PP-TH-118 FREQUENCY AND GENDER DIFFERENCES OF POLYMORPHISMS IN THE TF AND TFPI GENES, AS RELATED TO PHENOTYPES IN PATIENTS WITH CORONARY HEART DISEASE
T. B. Opstad* (NO), A. Pettersen, S. Åkra, H. Arnesen, I. Seljeflot

PP-TH-119 DETECTION OF ENDOGENOUS TISSUE FACTOR LEVELS IN PLASMA USING THE CALIBRATED AUTOMATED THROMBOGRAM ASSAY
V. Ollivier* (FR), D. A. Manly, J. Wang, K. R. Machlus, A. S. Wolberg, M. Jandrot-Perrus, N. Mackman

PP-TH-120 VALIDATION OF THE INR CALIBRATION OF COAGUCHEK XS PT TEST STRIP MASTER LOTS AND ROUTINE PRODUCTION LOTS
W. Plesch* (DE), B. Scheffler, P. Herbel, A. Jünschke, T. Wickert

PP-TH-121 RFVIIa TREATMENT IN FACTOR VII DEFICIENCY : A SINGLE CENTRE EXPERIENCE
Z. Salcioglu* (TR), G. Aydogan, F. Akici, A. Akcay, D. Tugcu, H. S. Sen, Z. Baslar

PP-TH-122 ACTIVATION OF THE INTRINSIC PATHWAY OF BLOOD COAGULATION BY PARTICULATE MATTER IN VITRO
E. Kilinc* (NL), H. M. H. Spronk, I. Gosens, R. van Oerle, J. W. P. Govers-Riemslag, M. E. Gerlofs-Nijland, F. R. Cassee, H. ten Cate

PP-TH-123 EVALUATION OF NORMAL PLASMA MIXING STUDIES ON PROLONGED ACTIVATED PARTIAL THROMBOPLASTIN TIME IN CHINESE
J. Lin* (TW), S. Kuo, S. Yang, S. Chio, M. Shen

PP-TH-124 DIFFERENT SEVERITY OF CLINICAL MANIFESTATION IN PATIENTS WITH SEVERE HEMOPHILIA A
M. Faranoush* (IR), N. Danaie, R. Ghorbani, M. Rahmani, M. Jazebi, T. Shashaani, A. Mehrvar, A. Hedayatiasl, P. Vossough

PP-TH-125 HEMODYNAMIC EFFECTS OF COAGULATION BETA-FXIIa IN CONSCIOUS RATS
P. C. Papageorgiou* (CA), P. H. Backx, C. T. Chan, E. L. Yeo, J. S. Floras

PP-TH-126 STUDY OF THE MOLECULAR MECHANISM OF THE COAGULATION FACTOR X DEFICIENCY IN THREE CHINESE PEDIGREES
Q. Chen* (CN), Q. Ding, X. Wang

PP-TH-127 CHARACTERIZATION OF TWO NOVEL MUTATIONS (VAL384ALA AND VAL384PHE) CAUSING FACTOR X DEFICIENCY IN TWO UNRELATED CHINESE FAMILIES
Q. Ding* (CN), X. Wang, T. Yu, H. Wang

PP-TH-128 FACTOR VIII AND VON WILLEBRAND FACTOR – THE CONFUSION OF THE 70’S PERSISTS TO TODAY
R. R. Montgomery* (US), S. L. Haberichter, M. Jozwiak, S. Fahs, Q. Shi

PP-TH-129 DEVELOPMENT OF NEW ASSAYS TO IDENTIFY THE CRP-VLDL COMPLEX
S. T. Abrams* (UK), C. Downey, J. Thachil, G. Wang, C. H. Toh

PP-TH-130 FACTOR XIIa INHIBITORS PREVENT FE(III)-CHLORIDE INDUCED THROMBOSIS IN MICE
S. Schmidbauer* (DE), C. Nerlich, T. Weimer, U. Kronthaler, H. Metzner, S. Schulte

PP-TH-131 THE PLASMA KALLIKREIN-KININ SYSTEM AND CLINICAL OUTCOME DURING FOLLOW-UP IN CHEST-PAIN PATIENTS
V. Pönitz* (NO), J. W. P. Govers-Riemslag, J. Konings, T. Brügger-Andersen, H. Grundt, H. ten Cate, H. Staines, D. W. T. Nilsen

PP-TH-132 GENETIC ANALYSIS OF A PEDIGREE WITH COMBINED FACTOR XII AND FACTRO XI DEFICIENCY
X. Ye* (CN), Y. Feng

PP-TH-133 MOLECULAR SIGNALING PATHWAY REGULATING PROLYLCARBOXYPEPTIDASEDEPENDENT KININ GENERATING CASCADE IN INFLAMMATION
Z. Shariat-Madar* (US), M. Ngo, D. Kolte, F. Mahdi

 

PP-TH-134 MEASUREMENT OF THE PHARMACODYNAMIC EFFECT OF DABIGATRAN ETEXILATE: THROMBIN CLOTTING TIME
J. Stangier, K. Wetzel, W. Wienen, J. van Ryn* (DE), K. Rathgen

PP-TH-135 COVALENT ANTITHROMBIN-HEPARIN AND THE PROTEIN C PATHWAY
M. C. van Walderveen* (CA), L. R. Berry, A. K. C. Chan

PP-TH-136 VALIDATION OF AN AUTOMATED CLOTTING ASSAY FOR MONITORING PLASMA ARGATROBAN LEVELS IN COMPARISON WITH A NOVEL ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (UPLC-MS/MS) METHOD
M. L. Snyder* (US), A. M. Winkler, F. Brierre, R. J. Molinaro

PP-TH-137 DIFFERENTIAL EFFECTS OF GENERIC ARGATROBANS ON THE PT/INR
O. Iqbal* (US), S. Masood, A. Gray, D. Hoppensteadt, J. Fareed

PP-TH-138 DIFFERENTIAL EFFECTS OF GENERIC ARGATROBANS ON WHOLE BLOOD ACTIVATION AND THROMBIN GENERATION MARKERS
O. Iqbal* (US), S. Masood, D. Hoppensteadt, J. Fareed

PP-TH-139 DETERMINANTS OF HIGH PROTEIN C LEVELS IN A LARGE DUTCH FAMILY
S. Roshani* (NL), M. C. Pintão, M. C. H. de Visser, C. Tieken, M. W. Tanck, H. R. Büller, I. M. Wichers, J. C. M. Meijers, S. Middeldorp, P. H. Reitsma

PP-TH-140 BIOPHYSICAL CHARACTERIZATION OF A DYSFUNCTIONAL ANTITHROMBIN VARIANT
S. Pedersen* (DK), M. Thomsen, S. R. Kristensen, A. Stensballe, D. E. Otzen

PP-TH-141 EFFECTS OF THROMBIN- OR Xa-INHIBITORS ON THE END PRODUCT OF COAGULATION: INCREASED POROSITY OF THE FIBRIN NETWORK CONTRIBUTES TO FIBRINOLYSIS
S. He, M. Blombäck* (SE), N. Bark, H. Jonhsson, H. Wallen

PP-TH-142 DRUG INTERACTIONS OF ORAL ANTITHROMBIN AND ANTI-Xa AGENTS WITH HEPARINIZED AND ORAL ANTICOAGULANT TREATED PATIENTS
S. Masood* (US), J. Cunanan, D. Hoppensteadt, D. van Thiel, J. Fareed

PP-TH-143 IDENTIFICATION OF MUTATION SITE AND FUNCTIONAL CHARACTERIZATION OF ABNORMAL PROTEIN C-TOTTORI
T. Hayashi* (JP), Y. Tanaka, Y. Okuyama, K. Yoshida, T. Okamoto, K. Iijima, K. Suzuki

PP-TH-144 GENETIC INFLUENCE OF CYP2C9 AND VKORC1 ON WARFARIN DOSE IN TWO GROUPS OF PATIENTS WITH DIFFERENT INR TARGET RANGES. (RELEVANCE OF A PREVIOUSLY DESCRIBED ALGORITHM FOR LOW INR RANGE
V. Le Cam-Duchez* (FR), M. Fretigny, N. Cailleux, Y. Benhamou, V. Barbay, H. Levesque, J. Borg

PP-TH-145 CONTAMINANTS IN HEPARIN! A CALL FOR SUBSTITUTE ANTICOAGULANTS
V. Bansal* (US), E. Litinas, D. Hoppensteadt, C. Adiguzel, J. Fareed

PP-TH-146 EFFECT OF ANGIOTENSIN(1-7) ON THE EXPRESSION OF E-SELECTIN INDUCED BY ANGIOTENSIN II AND ITS MECHANISM IN VASCULAR ENDOTHELIAL CELL
X. H. Shen* (CN), Z. B. Wen, X. F. He, N. Li, S. L. He

PP-TH-147 THE EFFECTS OF TANSHINONE 2A ON PLATELETS AND MEGAKARYOCYTES IN IMMUNE VASCULITIS
X. Li* (CN), M. Zhou, X. Li, M. Yang

 

PP-TH-148 MEASUREMENT OF THROMBIN-ALPHA-2-MACROGLOBULIN COMPLEXES GENERATED IN PLASMA
H. Vetr* (AT), S. Geiter, M. Graf, S. Knapp, B. R. Binder

PP-TH-149 CORRELATION BETWEEN PLASMA ACTIVITY OF ADAMTS-13 AND COAGULOPATHY, AND PROGNOSIS IN DISSEMINATED INTRAVASCULAR COAGULATION
J. Kim* (KR), J. Hyun, S. Park, H. Cho, H. Kim

PP-TH-150 CLEARANCE OF RECOMBINANT AND PLASMA DERIVED HUMAN FACTOR VIII IN A PERFUSED RAT LIVER MODEL
R. Appa* (DK), C. Theill, L. Hansen

PP-TH-151 INVESTIGATION OF CLEARANCE OF RECOMBINANT HUMAN FACTOR VIIa AND ITS VARIANTS IN A PERFUSED RAT LIVER MODEL
R. Appa* (DK), L. Hansen, C. Theill

PP-TH-152 THE DETECTION OF PROS1 DELETIONS, A COMMON CAUSE OF PROTEIN S DEFICIENCY
R. B. Wheeler* (UK), J. Cutler, M. Mitchell

PP-TH-153 FACTOR VII-ACTIVATING PROTEASE IS ACTIVATED IN SEPSIS
S. Zeerleder* (NL), I. Bulder, F. Stephan, M. de Kruif, J. Hoogerwerf, T. van der Poll, L. Aarden

PP-TH-154 REEVALUATION OF “NORMAL” FACTOR VIII CONCENTRATION IN PLASMA
S. Butenas* (US), B. Parhami-Seren, A. Undas, K. G. Mann

PP-TH-155 THROMBIN GENERATION IN A THIN LAYER OF WHOLE BLOOD
S. Nijhuis* (NL), R. Apitz-Castro, C. H. Hemker

PP-TH-156 EVOLUTION OF PRIMARY HEMOSTASIS: ROLE OF TRYPSINS IN GILL HEMOSTASIS
S. Kim* (US), S. Rajpurohit, M. Carrillo, V. Kulkarni, P. Jagadeeswaran

PP-TH-157 DETERMINATION OF RISTOCETIN COFACTOR ACTIVITY: EYES ON BOTH DIRECTIONS
S. A. L. Montalvão* (BR), J. M. Annichino-Bizzacchi, M. S. Pereira, T. M. Machado, M. C. Ozelo, E. V. de Paula

PP-TH-158 ANTI-INFLAMMATORY EFFECT OF THROMBOLYTIC PREPARATION LONGOLYTIN
T. N. Serebryakova* (RU), T. S. Sharkova, L. V. Podorolskaya, I. S. Chromov

PP-TH-159 MEMBRANE BINDING OF FACTOR VIII C2 DOMAIN INHIBITED BY PHYSIOLOGIC SALINE IMPLYING A PROCESSIVE BINDING MECHANISM
V. A. Novakovic* (US), D. B. Cullinan, J. B. Baleja, G. E. Gilbert

PP-TH-160 ISOLATION AND CHARACTERIZATION OF A NOVEL FIBRINO(GENO)LYTIC SERINE PROTEINASE FROM AGKISTRODON BLOMHOFFII USSURIENSIS SNAKE VENOM
V. L. Karbovskyy* (UA), V. N. Skalka, A. N. Savchuk, G. L. Volkov

PP-TH-161 MOUSE THROMBIN IS UNIQUELY INSENSITIVE TO SODIUM ION AMONG REPRESENTATIVES OF MAMMALIAN, AVIAN AND REPTILIAN THROMBINS
N. Goli, W. G. Owen* (US)

PP-TH-162 AGE-RELATED REFERENCE RANGES OF C1-INH ACTIVITY AND ANTIGEN ARE IMPORTANT FOR EARLY DIAGNOSIS IN PAEDIATRIC HAE PATIENTS
W. Kreuz* (DE), E. Rusicke, I. Martinez-Saguer, E. Aygören-Pürsün, T. Klingebiel

 

PP-TH-163 PROTEIN Z LEVELS AND THROMBOTIC DISEASES – A META-ANALYSIS
F. Sofi* (IT), F. Cesari, S. Fedi, G. Broze, R. Abbate, G. Gensini

PP-TH-164 FUNCTIONAL STUDIES OF THE 5’UTR AND INTRON 7 SNPS OF THE TFPI GENE
G. Skretting* (NO), B. Stavik, C. F. Myklebust, P. Sandset, N. Iversen

PP-TH-165 KNOCK DOWN OF TFPI EXPRESSION IN SUM102 BREAST CANCER CELLS LEADS TO PRO-ANGIOGENIC PHENOTYPES
B. Stavik, G. Skretting* (NO), M. Sletten, E. Frengen, P. Sandset, N. Iversen

PP-TH-166 DEFIBROTIDE AUGMENTS THE ANTICOAGULANT ACTIONS OF HEPARIN AND LOW MOLECULAR WEIGHT HEPARINS
J. Fareed* (US), J. Cunanan, D. Hoppensteadt, O. Iqbal, C. Adiguzel

PP-TH-167 TYPE OF ANAESTHESIA DID NOT AFFECT THE EFFICACY AND SAFETY PROFILE OF DABIGATRAN ETEXILATE COMPARED WITH ENOXAPARIN FOR PRIMARY VENOUS THROMBOEMBOLISM PREVENTION FOLLOWING TOTAL KNEE OR HIP REPLACEMENT SURGERY
N. Rosencher* (FR), H. Noack, M. Feuring, A. Clemens, R. Friedman, B. I. Eriksson

PP-TH-168 DIFFERENTIAL EFFECTS OF TAK-442, A FACTOR Xa INHIBITOR, AND XIMELAGATRAN, A THROMBIN INHIBITOR ON FACTOR V-MEDIATED FEEDBACK ON COAGULATION CASCADE AND BLEEDING
N. Konishi* (JP), K. Hiroe, Y. Imaeda, T. Fujimoto, K. Kubo, M. Kawamura

PP-TH-169 IN PATIENTS PREDISPOSED TO CARDIOVASCULAR EVENTS, STANDARD DOSES OF DABIGATRAN ETEXILATE PREVENT POST-OPERATIVE VENOUS THROMBOEMBOLISM EFFECTIVELY AND WITH A GOOD SAFETY PROFILE
O. E. Dahl* (NO), C. Francis, A. Kurth, N. Rosencher, M. Feuring, A. Clemens, H. Noack, B. I. Eriksson, J. A. Caprini

PP-TH-170 STANDARD DOSE OF DABIGATRAN ETEXILATE IN PATIENTS UNDERGOING TOTAL HIP OR KNEE REPLACEMENT SURGERY WHO ARE PREDISPOSED TO POSTOPERATIVE VENOUS THROMBOEMBOLISM: EFFECTIVE AND GOOD SAFETY PROFILE
O. E. Dahl* (NO), C. Francis, A. Kurth, N. Rosencher, M. Feuring, H. Noack, B. I. Eriksson, J. A. Caprini

PP-TH-171 EVALUATION OF CLOTTING TIME ASSAYS FOR MONITORING ANTITHROMBOTIC ACTIVITIES OF THE FACTOR Xa INHIBITORS, APIXABAN AND RIVAROXABAN, AND THE THROMBIN INHIBITOR DABIGATRAN IN THE RABBIT
P. C. Wong* (US), E. J. Crain, C. A. Watson

PP-TH-172 MULTIPLEXED ANALYSIS OF IMMUNOGLOBULIN CLASS/ SUBCLASS AND EPITOPE SPECIFICITY OF ANTI-FVIII ANTIBODIES IN SIX CASES OF POSTPARTUM ACQUIRED HEMOPHILIA
P. Lapalud* (FR), S. Grosbrois, S. André, J. Borg, B. Guillet, Y. Gruel, M. Trossaert, B. Polack, C. Rotschild, J. Schved, H. Levesque, S. Lacroix-Desmazes, C. Granier, G. Lavigne-Lissalde

PP-TH-173 INTERFERENCE OF PLATELETS IN PLASMA ON THE APTT MIXING TEST
R. Ikeda* (JP), C. Morikawa, H. Yago

PP-TH-174 RIVAROXABAN DOWN REGULATES THE COAGULANT ACTIVITY INDUCED BY ACTIVATED MONOCYTES. COMPARISON WITH FONDAPARINUX
M. Laurent, U. Joimel, H. Li, S. Mirshahi, V. Lecam-Duchez, J. Borg, L. Cazin, J. Soria, C. Soria, R. Varin* (FR)

PP-TH-175 MAMMALIAN CELL SURFACE DISPLAY OF A FUNCTIONAL THROMBIN-INHIBITORY SERPIN
R. F. Gierczak* (CA), J. S. Sutherland, V. Bhakta, W. P. Sheffield

PP-TH-176 IN CALIBRATED AUTOMATED THROMBINOSCOPY, A DIRECT THROMBIN INHIBITOR (AR-H067637) CAUSES A SPURIOUS INCREASE OF THROMBIN GENERATION, DUE TO A TRANSIENT ALPHA2-MACRO-GLOBULIN-THROMBIN PEAK
R. J. Wagenvoord* (NL), J. Deinum, M. Elg, C. Hemker

PP-TH-177 ASSESSMENT OF THE EFFECT OF AR-H067637 ON THE ETP AS OBTAINED BY CALIBRATED AUTOMATED THROMBINOSCOPY
R. J. Wagenvoord* (NL), J. Deinum, M. Elg, C. Hemker

PP-TH-178 EFFECTS OF OVERSULFATED AND FUCOSYLATED CHONDROITIN SULFATES ON COAGULATION. CHALLENGES IN STUDIES OF ANTICOAGULANT POLYSACCHARIDES
R. J. C. Fonseca* (BR), S. M. C. G. Oliveira, V. H. Pomin, A. S. Mecawi, I. G. Araújo, P. A. S. Mourão

PP-TH-179 BOTHROJARACIN A PROTHROMBIN INHIBITOR WITH POTENT ANTI-THROMBOTIC ACTIVITY
R. B. Zingali* (BR), R. R. Q. Monteiro, F. F. S. Frattani, M. Assafim

PP-TH-180 EVALUATION OF MIXING STUDIES INTERPRETATION CRITERIA AND LUPUS ANTICOAGULANTS (LA) CONFIRMATORY TEST IN PEDIATRIC PATIENTS
S. Estelle* (US), M. Chitlur, L. Llanto, J. Thul, L. Kodali, M. Rajpurkar, J. M. Lusher

PP-TH-181 THE ANTI-COAGULANTS ASIS OR APC DO NOT PROTECT AGAINST RENAL ISCHEMIA/ REPERFUSION INJURY
S. T. B. G. Loubele* (NL), A. C. Spek, P. Leenders, K. Hamulyak, R. A. Matthijsen, W. A. Buurman, C. J. Peutz-Kootstra, H. M. H. Spronk, H. ten Cate

PP-TH-182 EVALUATION OF A GENOTYPING TEST DETECTING VKORC1 AND CYP2C9 POLYMORPHISMS ASSOCIATED WITH COUMARIN-BASED ANTICOAGULANT SENSITIVITY IN PATIENTS
S. Campbell* (US), T. Patno, W. Cork

PP-TH-183 INFLUENCE OF A FLUOROGENIC SUBSTRATE ON THROMBIN GENERATION: WHEN IN SILICO SIMULATIONS PREDICT IN VITRO EXPERIMENTS
A. Carlo, S. Kerdélo* (FR), M. Gonidec, E. Arnaud, B. J. Woodhams

PP-TH-184 EFFECTS OF NOVEL FACTOR Xa INHIBITOR YM150 ON IN VITRO HUMAN PLATELET ACTIVATION AND AGGREGATION
S. Kaku* (JP), K. Suzuki, M. Sasamata, K. Miyata

PP-TH-185 PROTEIN Z/PROTEIN Z-DEPENDENT PROTEASE INHIBITOR COMPLEX IS A POOR INHIBITOR OF FACTOR Xa IN A PLASMA MILIEU
S. Mirshahi* (FR), C. Soria, M. Adam, J. Soria, B. J. Woodhams

PP-TH-186 EFFECTS ON FIBRIN NETWORK POROSITY OF ANTICOAGULANTS WITH DIFFERENT MODES OF ACTION
S. He, M. Blombäck* (SE), N. Bark, H. Wallén, M. Elg

PP-TH-187 EVALUATION OF A NEW ANTI-Xa HEPARIN ASSAY
S. J. Davidson* (UK)

PP-TH-188 THROMBIN GENERATION IN ACQUIRED AND INHERITED PROTEIN S DEFICIENCY
A. Wong, S. Rodgers, T. Stanford, E. Duncan, B. Dale, R. Baker, S. J. McRae* (AU)

PP-TH-189 INFLUENCE OF THE ENDOTHELIAL CELL PROTEIN C RECEPTOR (EPCR) GENE (PROCR) ON PROTEIN C DEFICIENCY EXPRESSION
B. Saposnik, M. Alhenc-Gelas, J. F. Abgrall, M. F. Aillaud, C. Boinot, P. de Moerloose, M. Dreyfus, J. Emmerich, M. Gouault-Heilman, B. Jude, C. Ternisien, B. Tardy, C. Vergnes, M. Aiach, S. Gandrille* (FR)

PP-TH-190 PROFILING OF DIFFERENTIALLY EXPRESSED GENES ASSOCIATED WITH INHIBITOR DEVELOPMENT IN HEMOPHILIA A
S. Hwang* (KR), H. C. Kim, H. Lee, K. Yoo, H. J. Kim, H. Kim

PP-TH-191 MASS TRANSPORT PROPERTIES OF ANTITHROMBIN III ISOFORMS SUGGEST INTRODUCTION OF ALPHA-ANTITHROMBIN AT THE TELEOST TO TETRAPOD TRANSITION WAS ADAPTIVE IN THE CONTEXT OF THE EVOLUTIONARY SWITCH TO HIGH-PRESSURE DOUBLE CIRCULATORY SYSTEMS, WHICH REQUIRE RAPID
S. C. Bock* (US), B. Leng

PP-TH-192 A FLUORESCENCE MICROPLATE ASSAY FOR DIRECT QUANTIFICATION OF HEPARINS AND OTHER SULFATED CARBOHYDRATES
S. Alban* (DE), S. Lühn

PP-TH-193 PROTHROMBIN TIME AS A SIMPLE SCREENING METHOD TO IDENTIFY HEPARINS CONTAMINATED WITH OSCS AND SIMILAR COMPOUNDS
S. Alban* (DE), S. Lühn

PP-TH-194 ACTIVATION OF ANTITHROMBIN BY TWO SITES MUTATIONS
T. Koide* (JP), H. Kawajiri, E. Ooe, Y. Shoya

PP-TH-195 INHIBITION OF THROMBIN GENERATION IN HUMAN PLASMA BY THE ORAL DIRECT FACTOR Xa INHIBITOR DU-176B IN VITRO
T. Furugohri* (JP), C. Kamisato-Matsumoto, Y. Morishima, T. Shibano

PP-TH-196 COMPUTATIONAL MODELING OF WARFARIN THERAPY
T. Orfeo* (US), K. Brummel-Ziedins, M. Gissel, S. Butenas, K. G. Mann

PP-TH-197 ACTIVATED PROTEIN C REGULATES CARDIOMYOCYTE FUNCTION VIA EPCR AND PAR1
T. Dutt* (UK), E. Dubuis, M. Perez-Casal, G. Wang, G. Hart, C. Toh

PP-TH-198 ENOXAPARIN ATTENUATES ENDOTHELIAL DAMAGE WITH LESS BLEEDING COMPARED TO UNFRACTIONATED HEPARIN IN ENDOTOXEMIC RATS
T. Iba* (JP)

PP-TH-199 THROMBIN GENERATION IN THE ASSESSMENT OF SUSPECTED ANTIBODIES TO FACTOR X
T. H. Tran* (CH), G. Favre, G. A. Marbet

PP-TH-200 CLINICAL SITE EVALUATION OF A NEW LIQUID HEPARIN ASSAY
V. Krougliak* (US), J. Gabbeta, C. Kung, M. Triscott

PP-TH-201 EX VIVO NEUTRALIZATION OF ENOXAPARIN IN PRIMATES BY A NOVEL HEPARIN ANTAGONIST
W. P. Jeske* (US), E. Litinas, J. Emanuele, D. Hoppensteadt, E. McAllister

PP-TH-202 EVALUATION OF THE DIRECT FACTOR Xa INHIBITOR APIXABAN IN RAT MODELS OF THROMBOSIS AND HEMOSTASIS
W. A. Schumacher* (US), J. S. Bostwick, A. B. Stewart, B. Xin, P. C. Wong

PP-TH-203 THE PREVALENCE AND GENETIC BACKGROUND OF FACTOR VIII INHIBITORS IN CHINESE HEMOPHILIA A PATIENTS
X. Wang* (CN), Q. Ding, R. Yang, Y. Zhao, J. Wu, J. Sun, X. Zhang, H. Wang

PP-TH-204 ACQUIRED FACTOR X DEFICIENCY: DIFFICULTIES TO ESTABLISH ETIOLOGIC DIAGNOSIS
Z. Kaci* (DZ), H. Ahmidatou, N. Zidani, K. Chennoukh, Y. Berkouk, M. Belhani

PP-TH-205 PROLONGATION OF THE APTT MAY DEPEND ON INHIBITION OF CONTACT FACTORS
Z. Volovyk* (US), D. M. Monroe, M. Hoffman

PP-TH-206 OBESITY INCREASES FIBRINOGEN LEVELS IN PREGNANCY
M. P. Smrtka* (US), B. H. Thames, M. Beckman, P. Rawlins, A. H. James

PP-TH-207 THE EFFICACY OF FIBRINOGEN CONCENTRATE IN TREATING EXCESSIVE BLEEDING IN AORTIC SURGERY
N. Rahe-Meyer* (DE), K. Tanaka, C. Solomon, A. Osthaus, K. Goerlinger, S. Piepenbrock, M. Pichlmaier

PP-TH-208 RECOVERY OF FIBRINOGEN PLASMA LEVEL AFTER ADMINISTRATION OF FIBRINOGEN CONCENTRATE FOR HEMOSTATIC THERAPY IN AORTIC SURGERY
N. Rahe-Meyer* (DE), K. Tanaka, K. Goerlinger, M. Pichlmaier, A. Osthaus, S. Piepenbrock, C. Solomon

PP-TH-209 EFFECTS OF ANTI-RETROVIRAL THERAPY ON HAEMOSTATIC AND HAEMORHEOLOGICAL PARAMETERS IN HIV/AIDS PATIENTS
O. A. Awodu* (NG), A. O. Adebayo, A. A. Famodu

PP-TH-210 IN VITRO PROPERTIES OF BLOOD BANK PRODUCED FIBRIN SEALANTS FROM SINGLE DONOR HUMAN PLASMA
P. Eshghi* (IR), A. Hashemi, N. Amirizadeh, H. Abolghasemi

PP-TH-211 DETERMINATION OF ACTIVATED FACTOR XIII IN PLASMA AS A MARKER OF ACTIVATION OF COAGULATION
S. Mirshahi* (FR), C. Soria, J. Chidiac, G. Kierzek, R. Varin, R. Batista, L. Drouet, B. J. Woodhams, J. Soria

PP-TH-212 ANALYSIS OF FIBRIN STRUCTURE AND FUNCTION IN MAN EXPOSED TO TRANSIENT DIESEL EXHAUST
S. Metassan* (UK), M. N. Routledge, A. J. Lucking, J. A. Scott, N. L. Mills, D. E. Newby, R. A. S. Ariëns

PP-TH-213 KINETICS OF FIBRINOPEPTIDES RELEASE FROM FIBRINOGEN ADSORBED ON A SURFACE
T. Riedel* (CZ), E. Brynda, M. Houska, J. Suttnar, J. E. Dyr

PP-TH-214 MOLECULAR SIMULATIONS OF FORCED UNFOLDING OF FIBRIN MONOMERS
V. Barsegov* (US), R. Dima, J. W. Weisel, R. I. Litvinov, A. Zhmurov

PP-TH-215 CRYPTIC HEPATOPATHY AND HYPOFIBRINOGENEMIA IN A PATIENT COMPOUND HETEROZYGOUS FOR A KNOWN MUTATION IN THE FIBRINOGEN GAMMA CHAIN (ARG375TRP) AND A NOVEL MUTATION IN THE FIBRINOGEN BETA CHAIN (PRO70SER)
W. A. Hassenpflug* (DE), K. Franke, E. Grabhorn, H. Schäfer, R. Schneppenheim, M. Meyer

PP-TH-216 FACTOR XIII SUBUNITS IN NON-STIMULATED AND STIMULATED HUMAN TEARS AND IN TEARS PRODUCED FOLLOWING PENETRATING KERATOPLASTY
Z. Z. Orosz* (HU), É. Katona, A. Facskó, A. Berta, L. Muszbek

 

PP-TH-217 FIBRINOLYTIC SYSTEM ASSESSMENT IN HEMODIALYSIS PATIENTS WITH AND WITHOUT THROMBOTIC COMPLICATIONS
L. M. S. Dusse* (BR), D. R. A. Rios, A. C. Simões E Silva, V. Rodrigues, A. V. Santos, B. A. Lwaleed, M. G. Carvalho

PP-TH-218 FIBRINOLYSIS IN PREECLAMPSIA
L. C. Godoi, L. S. Dusse* (BR), H. S. Madeira, B. A. Lwaleed, M. G. Carvalho

PP-TH-219 ROLE OF KRINGLES OF PLASMINOGEN (PG) AND PLASMIN-STAPHYLOKINASE ACTIVATOR COMPLEX (PM-STA) IN TERNARY ENZYME-SUBSTRATE COMPLEX FORMATION
M. Y. Levashov* (RU), R. Aisina, R. Kramor, K. Gershkovich, S. Varfolomeyev

PP-TH-220 SYSTEMIC PRIMARY FIBRINOLYSIS DUE TO TISSUE PLASMINOGEN ACTIVATOR (TPA) PRODUCING METASTATIC BREAST CANCER
H. V. K. Naina, M. M. Patnaik* (US), U. Ali, A. Behfar, C. Dong, A. A. Ashrani

PP-TH-221 IS THERE ANY EFFECT OF OBESITY ON THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR LEVELS IN POSTMENOPAUSAL WOMEN
B. Taskiran, S. Guldiken, M. Demir* (TR), T. Kilic-Okman, E. Arikan, B. Turgut, A. Tugrul

PP-TH-222 THE PLASMA LEVELS OF THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR IN PATIENTS WITH PRIMARY HYPOTHYROIDISM BEFORE AND AFTER TREATMENT
N. Ermantas, S. Guldiken, M. Demir* (TR), A. Tugrul

PP-TH-223 UNFRACTIONATED HEPARIN OR FONDAPARINUX IN ELDERLY PATIENTS WITH NONST-ELEVATION ACUTE CORONARY SYNDROME: DIFFERENT EFFECT ON FIBRINOLYTIC STATUS AT DAY 8
O. Averkov* (RU), L. Skutnitskaya, Z. Kobalava

PP-TH-224 THE EXTREME C-TERMINUS OF ANTIPLASMIN IS MOST IMPORTANT IN ACCELERATING THE PLASMIN-ANTIPLASMIN INTERACTION
T. Sofian, B. Lu, C. Hitchen, A. J. Horvath, P. B. Coughlin* (AU)

PP-TH-225 TREATMENT OF CENTRAL CATHETER RELATED VENOUS THROMBOSIS WITH LOW DOSE INTRACLOT INJECTIONS OF TPA
R. Chang, R. Chang* (US), A. W. Kam, E. Chen, J. N. Lozier, M. K. Horne

PP-TH-226 MECHANISM OF THE ACTION OF THE PLASMINOGEN MODULATOR SMTP
R. Narasaki* (JP), H. Koide, H. Shiraishi, K. Hasumi

PP-TH-227 MECHANISM OF INHIBITORY ACTION OF ANGIOSTATIN ON PLASMINOGEN (PG) ACTIVATION BY TISSUE PLASMINOGEN ACTIVATOR (TPA) AND UROKINASE (UPA)
R. B. Aisina* (RU), L. Mukhametova, N. Prisyazhnaya, D. Gulin, K. Gershkovich, S. Varfolomeyev

PP-TH-228 INFLUENCE OF HEAT-PROOF SUBSTANCE CONTAINED IN NATTO ON BLOOD CIRCULATION
T. Ohsugi* (JP), E. Sumida, H. Sumi

PP-TH-229 UROKINASE-TYPE PLASMINOGEN ACTIVATOR INDUCES HEPATIC DIFFERENTIATION OF EMBRYONIC STEM CELL
T. Seki* (JP), Y. Hasebe, G. Watanabe, H. Nakashima, K. Sawada, S. Hanazawa, M. Harashima, Y. Ito, N. Okumura, T. Ariga

PP-TH-230 IN VITRO COMPARISON OF FIBRINOLYTIC PROPERTIES OF DIRECT THROMBOLYTICS
V. Novokhatny* (US), J. Nixon, C. Li, J. Bromirski, J. Hunt, P. Scuderi, S. R. Petteway

PP-TH-231 A UNIQUE RECOMBINANT PLASMIN MOLECULE LACKING KRINGLES 2-5 EXHIBITS COMPARABLE HEMOSTATIC SAFETY AND EFFICACY AS FULL-LENGTH, PLASMADERIVED PLASMIN
V. J. Marder* (US), S. Manyak, T. Gruber, J. Hunt, J. Bromirski, A. Goyal, P. Scuderi, S. R. Petteway Jr, V. Novokhatny

PP-TH-232 DOSE RESPONSE STUDY OF INTRA-ARTERIAL PLASMIN TO RECANALIZE THE THROMBO-OCCLUDED RABBIT MIDDLE CEREBRAL ARTERY
R. Jahan, T. Gruber, A. Goyal, V. Arora, V. J. Marder* (US)

PP-TH-233 DEVELOPMENT OF NOVEL TECHNOLOGY TO ANALYZE THE PROCESS OF INTRAVASCULAR THROMBOLYSIS
Y. Magari* (JP)

PP-TH-234 ROTEM® THROMBOELASTOMETRY IN LIVER TRASPLANTATION: COULD IT PREDICT POSTRANSPLANTATION GRAFT PERFORMANCE
A. F. Minou* (BY), A. M. Dzyadzko

PP-TH-235 SELECTION OF A FLUOROGENIC MARKER FOR USE IN WHOLE BLOOD (WB) ENZYMATIC ASSAYS
E. Lebra, A. Carlo* (FR), H. Apan, V. El Qacemi, G. Quentin, B. J. Woodhams, E. Arnaud

PP-TH-236 TESTING OF LOW MOLECULAR WEIGHT HEPARIN DURING HEMODIALYSIS
E. Vlasova* (RU), I. Vasilenko, V. Samoylenko, V. Suslov

PP-TH-237 PIVOTAL ROLE OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) FOR LOCAL REGULATION OF TISSUE FACTOR (TF) -INDUCED THROMBIN GENERATION IN MONOCYTES ISOLATED FROM HUMAN BLOOD
G. B. Manjunath* (NO), F. X. Gruber, M. Sovershaev, H. I. Appelbom, B. Østerud, L. C. Petersen, S. Pankiv, J. Hansen

PP-TH-238 THE EFFECT OF THYROXINE AND THYROTROPIN (TSH) LEVELS ON THE COAGULATION SYSTEM
J. Debeij* (NL), S. C. Cannegieter, B. van Zaane, J. W. A. Smit, N. P. M. van der Kley-Corssmit, F. R. Rosendaal, J. A. Romijn, O. M. Dekkers

PP-TH-239 CARBON MONOXIDE RELEASING MOLECULE 3 (CORM-3) INHIBITS ARTERIAL THROMBOSIS IN RATS
K. Kramkowski* (PL), A. Mogielnicki, R. Motterlini, S. Chlopicki, W. Buczko

PP-TH-240 BIOLOGICAL VARIABILITY OF COAGULATION TESTS
M. W. Besser* (UK), L. Figueiredo, T. Baglin, R. Luddington

PP-TH-241 QUANTIFICATION OF PROTHROMBIN FRAGMENT 1+2 BY LOCI® TECHNOLOGY*
M. Ehm* (DE), H. Althaus, B. Fischer, A. Muth, M. Pfeiff, S. Teigelkamp

PP-TH-242 EFFECT OF IN-VITRO CRYSTALLOID DILUTION ON ENDOGENOUS THROMBIN POTENTIAL (ETP) IN HEALTHY VOLUNTEERS (HV) AND PATIENTS WITH A HISTORY OF VENOUS THROMBOSIS (VT) OR HEPATIC CIRRHOSIS (HC)
N. Jones* (UK), J. Kaur, A. Riddell, C. Melikian, S. Mallett

PP-TH-243 THROMBIN REDUCES TIME TO PEAK ON TISSUE FACTOR INDUCED THROMBIN GENERATION IN HUMAN AORTIC SMC VIA ACTIVATION OF PAR 3 AND 4 RECEPTORS
P. Vidwan* (US), A. Pathak, S. Sheth, G. A. Stouffer

PP-TH-244 FURTHER CHARACTERISATION OF AN ANDROGEN RESPONSE ELEMENT IN THE HUMAN PROTEIN C GENE PROMOTER
K. Korfi, K. J. Cameron, P. R. Winship* (UK)

PP-TH-245 RESPONSES TO LOW-DOSE VITAMIN K TREATMENT FOR WARFARIN OVERDOSE AND VKORC1 SINGLE NUCLEOTIDE POLYMORPHISM (SNP)
R. Deoisares, P. Rojnuckarin* (TH)

PP-TH-246 HIGH PROCOAGULANT ACTIVITY IN SUBRETINAL FLUID IN PRIMARY RETINAL DETACHMENT DISORDER
R. Al Dieri* (NL), L. J. A. G. Ricker, E. C. La Heij, A. Kijlstra, H. C. Hemker

PP-TH-247 FAST QUANTITATIVE AND GLYCOMIC VARIATIONS OF ANTITHROMBIN AFTER BIRTH
R. Teruel* (ES), J. Corral, I. Martínez-Martínez, A. Miñano, A. Ordóñez, B. Sánchez-Vega, V. Vicente, C. Martínez

PP-TH-248 WHOLE BLOOD PROCOAGULANT ACTIVITY IN HEALTHY VOLUNTEERS IS DECREASED FOLLOWING ORANGE JUICE INTAKE
E. Napoleone, A. Cutrone, F. Zurlo, G. Colavecchia, A. di Castelnuovo, L. Giordano, A. de Curtis, L. Iacoviello, C. Cerletti, D. Rotilio, G. de Gaetano, M. B. Donati, R. Lorenzet* (IT)

PP-TH-249 WHOLE BLOOD PROCOAGULANT ACTIVITY AS A POSSIBLE CELLULAR MARKER OF CARDIOVASCULAR RISK
E. Napoleone, A. Cutrone, F. Zurlo, A. de Curtis, F. Gianfagna, B. Vohnout, L. Iacoviello, G. de Gaetano, M. B. Donati, R. Lorenzet* (IT)

PP-TH-250 THE ARTERIO-VENOUS DIFFERENCE OF HEMOSTASIS PARAMETERS IN VARIOUS TYPES OF ENERGY DEFICIENCY
S. V. Sinkov* (RU), I. B. Zabolotskikh, K. D. Zybin, S. V. Grigoriev

PP-TH-251 THE ROLE OF INSTRUMENTAL DIAGNOSTIC TECHNIQUES IN THE ASSESSMENT OF THE DEGREE OF HEMOSTATIC DYSFUNCTION
S. V. Sinkov* (RU), I. B. Zabolotskikh, S. A. Shaposhnikov

PP-TH-252 IDENTIFICATION AND CHARACTERIZATION OF HIGH AFFINITY SMALL MOLECULE INACTIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1
S. Li* (US), J. M. Cale, M. Warnock, C. Emal, D. A. Lawrence

PP-TH-253 CALIBRATED AUTOMATED THROMBOGRAPHY (CAT) IN PLATELET POOR PLASMA IN ADULTS
S. Petros* (DE), T. Schneider, T. Siegemund, R. Siegemund

PP-TH-254 THROMBIN GENERATION IN PATIENTS WITH SEPSIS
S. Petros* (DE), P. Kliem, T. Siegemund, R. Siegemund, S. Kindler

PP-TH-255 EFFECT OF IN VIVO REDUCTION IN RED CELL MASS ON RESULTS OF CANINE WHOLE BLOOD THROMBOELASTOMETRY
S. A. Smith* (US), M. McMichael, A. Galligan, K. Swanson, J. H. Morrissey

PP-TH-256 DIFFERENTIAL EFFECTS OF POLYPHOSPHATE ON BLOOD CLOTTING
S. A. Smith* (US), S. H. Choi, J. Huyck, J. H. Morrissey

PP-TH-257 HEPARIN ECCELERATES FIBRINOLYTIC AND THROMBOLYTIC FUNCTION OF LONGOLYTIN
T. S. Sharkova* (RU), L. V. Podorolskaya, T. N. Serebryakova

PP-TH-258 LOW-MOLECULAR-WEIGHT HEPARIN AND TRANEXAMIC ACID FOR CHRONIC DIC IN PROSTATE CANCER - A CASE REPORT
T. Vucemilo* (HR), D. ?turm, M. Banoviæ, G. Krajaèiæ,Karas

PP-TH-259 THE (GT)N LOCUS OF THE VON WILLEBRAND FACTOR (VWF) GENE PROMOTER PREDICTS INCREASED VWF LEVELS IN RESPONSE TO GLUCOCORTICOID EXCESS
V. Daidone* (IT), F. Sartorello, M. Cattini, E. Pontara, L. Gallinaro, A. Pagnan, A. Casonato

PP-TH-260 PLASMIN-INDUCED THROMBIN FORMATION EXPLAINS MILD HAEMORRHAGE IN FIBRINOLYTIC DISORDERS
W. L. van Heerde* (NL), S. Croockewit, P. Lap, A. Loof, K. Verbeek, J. Boezeman, I. Novakova, M. van Kraaij, B. Verbruggen

PP-TH-261 FACTOR VA C1 AND C2 DOMAINS PARTICIPATE IN PHOSPHATIDYLETHANOLAMINE MEMBRANE BINDING
X. Liang* (US), M. Quinn-Allen, W. H. Kane

PP-TH-262 FURTHER STUDIES ON HEMOSTATIC ACTIVATION IN SICKLE CELL DISEASE : ROLE OF HEMOLYSIS AND TYPE-II PHOSPHATIDYLSERINE-POSITIVE ERYTHROCYTES
Y. B. Setty* (US), N. S. Key, M. J. Stuart

PP-TH-263 ANTICARDIOLIPIN AND ANTI-BETA 2 GLYCOPROTEIN 1 ANTIBODIES ARE REQUIRED FOR THE CLINICAL DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME
C. Gardiner* (UK), J. Hills, S. J. Machin, H. Cohen

PP-TH-264 PHOSPHOLIPID COMPOSITION IMPACT ON DILUTE THROMBOPLASTIN SENSITIVITY TO LUPUS ANTICOAGULANTS
K. M. Cawthern* (US), R. Bottenus, D. Diaz, M. X. Triscott

PP-TH-265 CATASTROPHIC ANTIPHOSPHOLIPID ANTIBODY SYNDROME (CAPS) IN CHILDREN: SUCCESSFUL MANAGEMENT WITH AGGRESSIVE DIRECT THROMBIN INHIBITION, PHARMACOMECHANICAL THROMBOLYSIS, AND IMMUNOMODULATORY THERAPY
M. J. Manco-Johnson* (US), M. Wang, N. A. Goldenberg, J. Soep, E. Pounder, C. Knoll

PP-TH-266 BIOPHYSICAL CHARACTERIZATION OF THE COMPLEXES BETWEEN B2GPI AND THE LIGAND-BINDING LA MODULES FROM THE LIPOPROTEIN RECEPTORS
C. Lee, A. de Biasio, N. Beglova* (US)

PP-TH-267 MARKERS OF INFLAMMATION AND ENDOTHELIAL CELLS ACTIVATION IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME DEPENDING ON THROMBOSIS LOCALIZATION
N. V. Seredavkina* (RU), T. M. Reshetnyak, E. N. Alexandrova, A. A. Novikov, E. S. Much, M. V. Cherkasova, E. L. Nasonov

PP-TH-268 ASSOCIATION BETWEEN HOMOCYSTEINE, ANTICARDIOLIPIN AND ANTIBETA2 GLYCOPROTEIN-I ANTIBODIES IN PATIENTS WITH CORONARY ARTERY DISEASE
O. A. Smirnova* (RU), V. M. Shmeleva, V. A. Kobilyanskaya, L. P. Papayan

PP-TH-269 CLINICAL MANIFESTATIONS OF LUPUS ANTICOAGULANTS IN CHILDREN
O. M. Serbic* (RS), M. Kuzmanovic, G. Vlahovic, D. Veljkovic, S. Pasic, D. Micic

PP-TH-270 TISSUE FACTOR -603A/G POLYMORPHISM AND TISSUE FACTOR LEVELS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME
R. Kahraman, V. Hancer, R. Diz-Kucukkaya* (TR)

PP-TH-271 THE MANAGEMENT OF ELEVATED APL IN PREGNANCY
R. Apostolovska* (MK), T. Balkanov, V. Dejanova, K. Dimitrovski, S. Atanasova, I. Nikoloska, L. Stojanovska-Trajkovska, V. Neceva

PP-TH-272 LUPUS ANTICOAGULANT IN A CHILD WITH CELIAC DISEASE- AN UNCOMMON ASSOCIATION
S. Naseem* (IN), J. Ahluwalia, D. Suri, S. Singh

PP-TH-273 ANTI-BETA-2-GLYCOPROTEIN-I IGG ANTIBODIES AND ANTI-CARDIOLIPIN IGG ANTIBODIES DO NOT PREDICT THROMBOSIS IN PATIENTS WITH A PERSISTENT LUPUS ANTICOAGULANT
S. Koder* (AT), R. Vormittag, C. Zoghlami, S. Panzer, P. Quehenberger, I. Pabinger

PP-TH-274 ROLE OF CALCIUM IONS IN THE BINDING OF BETA2-GLYCOPROTEIN I TO CARDIOLIPIN IN AN ELISA ASSAY
S. Olivieri* (IT), M. Tonello, A. Cavazzana, A. Bontadi, A. Banzato, E. Bison, V. Pengo, A. Ruffatti

PP-TH-275 LUPUS ANTICOAGULANT – WITH HYPOPROTHROMBINAEMIA: A REPORT OF 2 CASES
S. C. Nair* (IN), N. Arora, N. V. Patkar, S. Baidya, L. G. Mattew, P. D. Moses

PP-TH-276 SEVERE BLEEDING DUE TO ACQUIRED HYPOPROTHROMBINEMIA-LUPUS ANTICOAGULANT SYNDROME.CAS REPORT AND REVIEW OF LITERATURE
T. K. Dib* (DZ), C. Abi-Ayad, S. Ayad, M. Gheras, S. Brixi, A. Reghis

PP-TH-277 THROMBOCYTOPENIA IN ANTIPHOSPHOIPID SYNDROME
T. M. Reshetnyak* (RU), I. B. Shtivelband, E. N. Alexandrova, A. A. Novikov, N. V. Seredavkina, L. V. Kondratieva, E. V. Ostryakova, E. L. Nasonov

PP-TH-278 CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME AND OBSTETRIC COMPLICATIONS
V. O. Bitsadze* (RU), S. M. Baimuradova, D. H. Hizroeva, S. V. Akinshina, A. D. Makatsariya

PP-TH-279 INTIMA-MEDIA THICKNESS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME
G. Malek, W. Z. Tomkowski* (PL), P. Kuca, M. Dybowska, J. Burakowski, M. Meissner

PP-TH-280 CORONARY ARTERIES CALCIUM SCORING IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME
P. Kuca, W. Z. Tomkowski* (PL), G. Malek, M. Dybowska, J. Burakowski, M. Meissner

PP-TH-281 THE EFFECT OF LUPUS ANTICOAGULANTS AND APC RESISTANCE ON PROTEIN S ACTIVITY ASSAY
Z. Cao* (US), R. Bottenus, D. Sanchez, M. Triscott

PP-TH-282 INHERITED OR ACQUIRED THROMBOPHILIC ALTERATIONS (TAS) IN PATIENTS WITH FOR SUPERFICIAL VEIN THROMBOSIS (SVT)
C. Legnani* (IT), M. Cini, C. Pili, G. Lo Manto, M. Frascaro, O. Boggian, G. Palareti

PP-TH-283 ASSESSMENT OF RACE, GENDER AND MORTALITY FROM A LARGE NATIONWIDE SAMPLE OF PATIENTS ADMITTED FOR PULMONARY EMBOLISM IN THE UNITED STATES
D. M. Courtney* (US), R. K. Khare

PP-TH-284 VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER MAJOR ORTHOPEDIC SURGERY: A MULTI-justify PROSPECTIVE OBSERVATIONAL STUDY
F. Altintas* (TR), ?. Öztürk, B. Atilla, R. Tözün, F. Pestilci

PP-TH-285 AUTOMATIZATION OF GENETIC ANALYSIS: FACTOR V LEIDEN, F2G20210A, F12C46T AND MTHFR C667T BY REAL TIME PCR
I. Coll, I. Tirado* (ES), E. Martínez-Sánchez, J. Souto, V. Orantes, J. Fontcuberta

PP-TH-286 HYPERTHYROIDISM IS ASSOCIATED WITH AN INCREASED RISK OF VENOUS THROMBOSIS
J. Debeij* (NL), B. van Zaane, O. M. Dekkers, J. W. A. Smit, J. A. Romijn, V. E. A. Gerdes, A. P. van Zanten, D. P. M. Brandjes, H. R. Büller, F. R. Rosendaal, S. C. Cannegieter

PP-TH-287 FUNCTIONAL CONSEQUENCES OF THE PROTHROMBOTIC SERPINC1 RS2227589 POLYMORPHISM ON ANTITHROMBIN LEVELS
A. I. Antón, R. Teruel, J. Corral* (ES), A. Miñano, I. Martínez-Martínez, A. Ordóñez, V. Vicente, B. Sánchez-Vega

PP-TH-288 COMPARISON OF THE CLINICAL HISTORY OF SYMPTOMATIC ISOLATED DISTAL DEEP-VEIN THROMBOSIS VERSUS PROXIMAL DEEP-VEIN THROMBOSIS IN 11086 PATIENTS: RESULTS FROM THE RIETE REGISTRY
J. Galanaud* (FR), S. Quenet, K. Guillot, I. Quéré, J. Sanchez Munoz-Torrero, C. Tolosa, M. Monreal, A. The Riete Investigators

PP-TH-289 QUANTITATIVE TRAIT LOCI INVOLVED IN THE REGULATION OF LIPOPROTEIN A (LPA) LEVELS: GENOME-WIDE LINKAGE ANALYSIS FROM THE GAIT PROJECT
S. López, A. Buil, J. Souto, J. Ordoñez, J. Blangero, F. Blanco-Vaca, J. Fontcuberta, L. Almasy, J. Soria* (ES)

PP-TH-290 QUANTITATIVE TRAIT NUCLEOTIDE ANALYSIS IN THE NNMT GENE: A GENETIC DETERMINANT FOR HOMOCYSTEIN LEVELS
M. Sabater-Lleal, J. Martín, A. Buil, M. Chillón, J. Souto, J. Blangero, J. Fontcuberta, F. Blanco-Vaca, J. Soria* (ES), L. Almasy

PP-TH-291 LIPID-LOWERING DRUGS, LIPID PARAMETERS AND VENOUS THROMBOEMBOLISM
K. Lacut* (FR), J. Malecot, A. Delluc, F. Couturaud, H. Kerspern, J. Carre, D. Mottier, E. Oger

PP-TH-292 CASE FATALITY RATE OF RECURRENT VENOUS THROMBOEMBOLISM AND MAJOR BLEEDING DURING AND FOLLOWING ANTICOAGULATION THERAPY
M. Carrier* (CA), G. Le Gal, P. S. Wells, M. A. Rodger

PP-TH-293 IS SCREENING FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN PATIENTS WITH A PREVIOUS PULMONARY EMBOLISM INDICATED
N. S. Gibson* (NL), S. Surie, V. E. A. Gerdes, B. J. Bouma, B. L. F. van Eck-Smit, H. R. Buller, P. Bresser

PP-TH-294 ASSOCIATION OF THE VEGF POLYMORPHISMS AND HAPLOTYPES WITH THE RISK OF OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURES IN POSTMENOPAUSAL WOMEN
N. Kim* (KR), Y. Chung, S. Hong, D. Shin, J. Lee

PP-TH-295 DIFFERENCES IN AETIOLOGICAL AND CLINICAL MANIFESTATIONS IN UPPER AND LOWER LIMB DEEP VENOUS THROMBOSIS PATIENTS FROM INDIA
N. Pai* (IN), S. Shetty, B. Kulkarni, K. Ghosh

PP-TH-296 PROTHROMBOTIC TENDENCY IN PATIENTS WITH HYPERTHYROIDISM
N. M. Antonijevic* (RS), B. Stojanovic, D. Mikovic, M. Kovac, S. Popovic, M. Petakov, B. Jakovljevic, A. Beletic, V. Djordjevic, B. Trbojevic, N. Radovanovic, I. Elezovic

PP-TH-297 THROMBOPHILIA MARKERS IN PORTAL VEIN THROMBOSIS
N. Ben Romdhane* (TN), S. Mahjoub, H. Kallel, R. Ellouze, H. Baccouche, Z. Manai

PP-TH-298 THROMBOPHILIC ABNORMALITIES IN TUNISIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
N. Ben Romdhane* (TN), R. Ellouze, S. Mahjoub, H. Kallel, L. Kallel, A. Filali

PP-TH-299 THROMBOPROPHYLAXIS IN HOSPITALIZED PATIENTS: CAN WE DO IT BETTER
P. Marchena Yglesias* (ES), E. Pesantes, R. Rey Santos, J. Burillo Lorente, F. Castro, F. Ribó Crusat, X. Martret Redrado, C. Paytubí Garí, J. Pérez Más, A. Domènech, M. Biosca Gómez de Tejada

PP-TH-300 HIGH FACTOR VIII IN EXTRA-HEPATIC PORTAL VEIN OBSTRUCTION
P. Bucciarelli* (IT), I. Martinelli, M. Primignani, R. Reati, F. Fabris, T. Battaglioli, A. Dell’Era, P. M. Mannucci

PP-TH-301 RELATIONSHIP BETWEEN HYPERHOMOCYSTEINEMIA AND LOW BONE MINERAL DENSITY
P. Bucciarelli* (IT), G. Martini, I. Martinelli, R. Nuti, P. M. Mannucci

PP-TH-302 PROSPECTIVE COHORT STUDY ON CARDIOVASCULAR RISK IN RETINAL VEIN OCCLUSION
M. T. Sartori, A. Donà, S. Piermarocchi, E. Pilotto, G. Saggiorato, A. Pagnan, P. Prandoni* (IT)

PP-TH-303 RISK STRATIFICATION AND OUTCOMES IN HEMODYNAMICALLY STABLE PATIENTS WITH ACUTE PULMONARY EMBOLISM. A PROSPECTIVE MULTICENTRE COHORT STUDY WITH THREE MONTHS OF FOLLOW-UP
C. Bova, R. Pesavento, A. Marchiori, A. Palla, I. Enea, V. Pengo, A. Visonà, A. Noto, P. Prandoni* (IT)

PP-TH-304 HEART DISEASES AS A POTENTIAL SOURCE OF PULMONARY EMBOLISM. FINDINGS FROM A CROSS-SECTIONAL SURVEY
P. Prandoni* (IT), R. Pesavento, H. T. Sorensen, N. Gennaro, F. Dalla Valle, I. Minotto, F. Perina, V. Pengo, A. Pagnan

PP-TH-305 STICKY PLATELET SYNDROME : ROLE OF FLOW CYTOMETRY
P. Kubisz* (SK), L. Barto?ová, J. Fedorová, P. Holl?, J. Sta?ko

PP-TH-306 NATIONAL REGISTRY OF THROMBOPHILIC STATES IN SLOVAK REPUBLIC
P. Kubisz* (SK), I. Plamenová, J. Chudej, K. Gregorová, L. Barto?ová, M. Dobrotová, P. Chud?, J. Sta?ko

PP-TH-307 A ONE-DAY SURVEY OF ANTICOAGULANT USE IN A FRENCH GENERAL HOSPITAL
P. Girard* (FR), C. Christidis, J. Cosserat, N. Cathala, D. Czitrom, J. Le Guillou, A. Lebuisson

PP-TH-308 FACTOR V LEIDEN IS MOST COMMONLY FOUND IN CATHETER-RELATED UPPER EXTREMITY DEEP VEIN THROMBOSIS; DATA FROM THE RIETE REGISTRY
P. di Micco* (IT), A. A. Visonà, V. V. Roldan, R. R. Lecumberri, A. A. Tirado, A. A. Niglio, M. M. Monreal

PP-TH-309 COMMON SUSCEPTIBILITY ALLELE ARE UNLIKELY TO CONTRIBUTE AS STRONGLY AS THE FV AND ABO LOCI TO VTE RISK: RESULTS FROM A GWAS APPROACH
D. Tregouet, S. Heath, N. Saut, C. Biron, J. Schved, G. Pernod, P. Galand, L. Drouet, D. Zelenika, I. Juhan-Vague, M. Alessi, L. Tiret, M. Lathrop, J. Emmerich, P. E. Morange* (FR)

PP-TH-310 INCIDENCE OF VENOUS THROMBOTIC EVENTS IN A DIVERSE AMERICAN PEDIATRIC INTENSIVE CARE UNIT POPULATION
R. A. Higgerson* (US), S. Hanson, K. A. Lawson, L. M. Christie, B. Totapally, J. McArthur, A. Brown

PP-TH-311 THE PREDICTIVE VALUE OF ICD-9-CM CODING FOR DEEP-VENOUS THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE)
R. H. White* (US), M. Garcia, B. Sadeghi, D. Tancredi, P. Zrelak, P. S. Romano

PP-TH-312 INFLUENCE OF GENDER ON THE CLINICAL PRESENTATION AND DIAGNOSIS OF DEEP-VEIN THROMBOSIS. FINDINGS FROM THE TULIPA REGISTRY
R. M. Bauersachs* (DE), H. Riess, V. Hach-Wunderle, H. Gerlach, H. Carnarius, S. Eberle, E. Rabe, S. M. Schellong

PP-TH-313 GENETIC RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN YOUNG WOMEN FROM NORTH-WESTERN RUSSIA
S. I. Kapustin* (RU), V. A. Kobilyanskaya, N. B. Saltykova, V. M. Shmeleva, M. N. Blinov

PP-TH-314 IS A LOW LEVEL OF APOLIPOPROTEIN A1 A RISK FACTOR FOR THROMBOSIS IN BUDD-CHIARI SYNDROME
S. Talens* (NL), J. Hoekstra, S. P. G. Dirkx, S. Darwish Murad, J. Garcia-Pagan, D. C. Valla, H. L. A. Janssen, F. W. G. Leebeek, D. C. Rijken

PP-TH-315 NATIONAL PROSPECTIVE COHORT STUDY OF VENOUS THROMBOEMBOLISM (VTE) MANAGEMENT IN THE CANADIAN OUTPATIENT SETTING: RECOVERY REGISTRY
S. R. Kahn* (CA), S. Schulman, J. Martineau, N. Komari, A. McLeod, C. Strulovitch, M. Blostein, J. Faucher, G. Gamble, W. Gordon, P. Kagoma, M. Miron

PP-TH-316 HOMOCYSTEINE PLASMA LEVELS AND MTHFR C677T MUTATION
S. M. Ouviña* (AR), A. La Greca, C. Mardaraz, G. Araujo, F. Negro, A. Ferro

PP-TH-317 LONG-TERM SURVIVAL AFTER VENOUS THROMBOEMBOLISM: A COHORT STUDY AMONG YOUNG WOMEN
S. E. Reitter* (AT), C. Laczkovics, T. Waldhoer, C. Vutuc, I. Pabinger-Fasching

PP-TH-318 PLASMA HOMOCYSTEINE LEVEL AND MTHFR MUTATION IN IRANIAN PATIENTS WITH THROMBOTIC EVENTS
T. Shashaani* (IR), M. Faranoush, S. Hejazi, M. Jazebi, F. Ala, N. Danaie

PP-TH-319 PRESENCE OF LOWER LIMB DEEP VEIN THROMBOSIS AND PROGNOSIS IN PATIENTS WITH SYMPTOMATIC PULMONARY EMBOLISM
T. Yamaki* (JP), H. Sakurai, K. Soejima, T. Kono, A. Hamahata

PP-TH-320 TYPE I ANTITHROMBIN DEFICIENCY IS MORE CLOSELY ASSOCIATED WITH VENOUS THROMBOEMBOLISM THAN TYPE II ANTITHROMBIN DEFICIENCY
T. Sakata, S. Kameda, M. Mitsuguro, A. Okamoto, M. Sano, Y. Kokubo, Y. Tsutsumi, T. Miyata* (JP)

PP-TH-321 THROMBOPHILIC RISK PROFILE IN PATIENTS WITH VENOUS THROMBOEMBOLISM IN NORTH-WESTERN RUSSIA
V. M. Shmeleva* (RU), S. I. Kapustin, M. N. Blinov

PP-TH-322 THE RISK OF VENOUS THROMBOSIS, INCLUDING CEREBRAL VEIN THROMBOSIS, AMONG WOMEN WITH THROMBOPHILIA AND ORAL CONTRACEPTIVE USE: A META ANALYSIS
N. Dayan, V. Tagalakis* (CA), C. Holcroft

PP-TH-323 THE EFFECT OF CASE DEFINITION ON THE APPARENT INCIDENCE OF VENOUS THROMBOEMBOLISM WITHIN A LARGE ADMINISTRATIVE HEALTH CLAIMS
DATABASE IN QUÉBEC, CANADA
V. Tagalakis* (CA), S. R. Kahn, Y. Moride, J. Bovin

PP-TH-324 THE RELATIONSHIP BETWEEN THE A6963G EPCR POLYMORPHISM AND VENOUS THROMBOEMBOLISM IN AMERICAN WHITES AND BLACKS: THE GATE STUDY
C. Destareck, C. Lally, J. Benson, D. Ellingsen, H. Austin, W. C. Hooper* (US)

PP-TH-325 THE RELATIONSHIP OF TWO POLYMORPHISMS OF THE TCF7L2 GENE AND VENOUS THROMBOEMBOLISM IN AMERICAN WHITES AND BLACKS: THE GATE STUDY
C. J. Bean, C. Lally, J. Benson, H. Austin, W. C. Hooper* (US)

PP-TH-326 LACK OF ASSOCIATION BETWEEN THE PHE204 ALLELE OF FACTOR XIII WITH VENOUS THROMBOEMBOLISM AND MYOCARDIAL INFARCTION
H. Austin, C. Lally, M. Pyle, W. C. Hooper* (US)

PP-TH-327 FACTOR V LEIDEN AND VENOUS THROMBOEMBOLISM RISK AMONG IDIOPATHIC AND PROVOKED CASES IN THE GATE STUDY
C. Lally, H. Austin, M. Beckman, M. Pyle, W. C. Hooper* (US)

PP-TH-328 POLYMORPHISMS IN THE THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR GENE AND RISK OF VENOUS THROMBOEMBOLISM
W. C. Hooper* (US), N. Dowling, C. Destaercke, C. Whitsett, C. Miller, M. Beckman, H. Austin

PP-TH-329 CONTRIBUTION OF HIGH LEVELS OF FACTORS VIII, IX AND XI TO THE RISK OF RECURRENT VENOUS THROMBOSIS IN HETEROZYGOUS FACTOR V LEIDEN CARRIERS
W. M. Lijfering* (NL), S. C. Christiansen, F. R. Rosendaal, S. C. Cannegieter

PP-TH-330 IMPLEMENTATION OF AN ELECTRONIC RISK ASSESSMENT TOOL WITH RULE BASED RECOMMENDATIONS FOR PREVENTION OF HOSPITAL ACQUIRED VENOUS THROMBOEMBOLISM
G. C. Moore, I. Clark, N. Gautam, G. Jeskins, N. Suggett, W. Lester* (UK)

PP-TH-331 COMBINED OCCURRENCE OF HEREDITARY PROTEIN C AND PROTEIN S DEFICIENCY IN TWO CHINESE FAMILIES WITH VENOUS THROMBOSIS
Y. Wu* (CN), G. Xu, Q. Ding, X. Xi, X. Wang, H. Wang

PP-TH-332 INFLAMMATORY STATE IN PATIENTS PRESENTING WITH VENOUS THROMBOSIS
Y. I. G. V. Tichelaar* (NL), W. M. Lijfering, H. G. M. Niesters, N. J. G. M. Veeger, A. B. Mulder, J. C. Kluin-Nelemans

PP-TH-333 ABO BLOOD GROUP AS A RISK FACTOR FOR VENOUS THROMBOSIS
Y. P. Adamczuk* (AR), M. L. Iglesias Varela, M. E. Martinuzzo, G. S. Cerrato, R. R. Forastiero

PP-TH-334 A NOVEL MUTATION (G2172?C) OF FACTOR V GENE IN A CHINESE FAMILY WITH ACTIVATED PROTEIN C RESISTANCE ASSOCIATED WITH VENOUS THROMBOEMBOLISM
H. Cai, B. Hua, L. Fan, Q. Wang, S. Wang, Y. Zhao* (CN)

PP-TH-335 SIGNIFICANCE OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) IN THE EARLY DEVELOPMENT OF HSCT-ASSOCIATED THROMBOTIC COMPLICATIONS
Y. Han* (CN), D. Wu, A. Sun, Z. Wang, C. Ruan

PP-TH-336 ASYMPTOMATIC MRI BRAIN ABNORMALITIES IN PATIENTS WITH THALASSEMIA INTERMEDIA
A. Taher* (LB), K. M. Musallam, W. Nasreddine, A. Beydoun

PP-TH-337 TISSUE FACTOR POLYMORPHISMS, TISSUE FACTOR LEVELS AND RISK FOR CRYPTOGENIC ISCHEMIC STROKE
A. Undas* (PL), D. Potaczek, M. Mazur, M. Pieculewicz, P. Podolec, W. Tracz

PP-TH-338 G-455A POLYMORPHISM OF B-FIBRINOGEN GENE AND THE RISK OF PREMATURE MYOCARDIAL INFARCTION
A. E. Gialeraki* (GR), L. Rallidis, M. Politou, E. Merkouri, D. Kremastinos, A. Travlou

PP-TH-339 GENETIC VARIATION IN COAGULATION FACTOR XIII AND THE RISK OF ARTERIAL THROMBOSIS: DIFFERENCES BETWEEN MYOCARDIAL INFARCTION AND ISCHAEMIC STROKE
B. Siegerink* (NL), F. R. Rosendaal, A. Algra

PP-TH-340 EFFECT OF A PERSONALIZED PHYSICAL ACTIVITY PROGRAMME ON WEIGHT REDUCTION AND ENDOTHELIAL PROGENITOR CELLS IN OVERWEIGHT SUBJECTS
F. Cesari* (IT), F. Sofi, I. Corsani, N. Pucci, R. Caporale, R. Abbate, G. Gensini, A. Casini

PP-TH-341 CLOPIDOGREL NONRESPONSIVENESS AND RISK OF CARDIOVASCULAR MORBIDITY – AN UPDATED META-ANALYSIS
F. Sofi* (IT), R. Marcucci, A. Gori, B. Giusti, R. Abbate, G. Gensini

PP-TH-342 THE FIRE UNDER THE ASH: WHICH ARE THE PREDICTORS OF RELAPSE AFTER ISCHEMIC HEART DISEASE
G. Corinaldesi* (IT), C. Corinaldesi

PP-TH-343 PLATELET GLYCOPROTEIN IIB/IIIA POLYMORPHISM AND RISK OF CARDIOVASCULAR EVENTS IN ASPIRIN-TREATED PATIENTS WITH STABLE CORONARY ARTERY DISEASE
I. Elalamy* (FR), T. Chakroun, F. Addad, Z. Dridi, F. Abderrazak, S. Hamdi, M. Hassine, M. Hassine, F. Betbout, G. Gerotziafas, M. Hatmi, H. Gamra

PP-TH-344 A RETROSPECTIVE CASE CONTROL STUDY ON THE ROLE OF HYPERCOAGULABILITY IN LATE STENT THROMBOSIS
K. Winckers* (NL), V. Poenitz, R. van Oerle, H. Spronk, T. M. Hackeng, D. W. T. Nilsen, H. ten Cate

PP-TH-345 THE ACTIVITY OF THROMBOMODULIN, TISSUE FACTOR AND CIRCULATING PROCOAGULANT PHOSPHOLIPIDS AS MARKERS FOR ACUTE MYOCARDIAL INFARCTION (AMI)
P. Vandreden, A. Rousseau, B. Lenormand, S. Fontaine, B. J. Woodhams, M. Vasse* (FR)

PP-TH-346 GENETIC POLYMORPHISM OF THE HOMOCYSTEINE AND FOLATE METABOLIZING ENZYMES: ASSOCIATION WITH PLASMA HOMOCYSTEINE AND PERIPHERAL ARTERIAL DISEASE RISK
N. A. Klenkova* (RU), S. I. Kapustin, A. A. Gyrgy, V. M. Shmeleva, L. P. Papayan, N. B. Saltykova, M. N. Blinov

PP-TH-347 ASSOCIATION OF ENDOGENOUS THROMBIN POTENTIAL (ETP) WITH CORONARY ARTERY DISEASE. AN ANGIOGRAPHY-BASED STUDY
N. Martinelli* (IT), O. Olivieri, N. Campostrini, A. Castagna, S. Friso, F. Pizzolo, P. Guarini, L. Annarumma, F. Busti, R. Corrocher, D. Girelli

PP-TH-348 ANTITHROMBOTIC EFFECTS OF BETA2-ADRENERGIC RECEPTOR BLOCKADE ON TOP OF BETA1-RECEPTOR BLOCKADE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR HEART FAILURE; A SYSTEMATIC REVIEW
O. R. de Peuter* (NL), F. Lussana, R. J. Peters, H. R. Büller, P. W. Kamphuisen

PP-TH-349 ELEVATED PLASMA FIBRIN D-DIMER AS A RISK FACTOR FOR VASCULAR DEMENTIA:THE THREE-CITY COHORT STUDY
L. Carcaillon, P. Gaussem* (FR), P. Ducimetière, M. Giroud, C. Tzourio, K. Ritchie, J. Dartigues, P. Scarabin

PP-TH-350 PROSPECTIVE EPIDEMIOLOGICAL STUDY OF THROMBOPHILIA AND INFLAMMATION MARKERS IN YOUNG HISPANIC PATIENTS WITH ARTERIAL THROMBOSIS
P. Casais* (AR), M. F. Alberto, L. Jones, G. Campregher, A. I. Woods, J. Paiva-Patiño, L. Keller, A. C. Kempfer, A. N. Blanco, S. S. Meschengieser, M. A. Lazzari

PP-TH-351 CLOTTING FACTORS, INFLAMMATORY MARKERS AND GLYCEMIC CONTROL IN DIABETES: ROLE IN CLOT STRUCTURE AND FIBRINOLYSIS
R. A. Ajjan* (UK), K. F. Standeven, S. Mughal, K. Hess, F. Phoenix, A. M. Carter, R. A. S. Ariens, P. J. Grant

PP-TH-352 CLOSE MONITORING OF HEMOSTASIS BY THROMBOELASTOMETRY DURING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
R. Paniccia* (IT), E. Antonucci, N. Maggini, S. Bevilacqua, M. Bonacchi, G. Sani, G. Olivo, D. Prisco, R. Abbate, G. F. Gensini

PP-TH-353 LOW-DOSE ASPIRIN THERAPY AFTER KIDNEY TRANSPLANTATION
R. Paniccia* (IT), E. Antonucci, M. Zanazzi, N. Maggini, N. Paudice, I. Ricci, R. Marcucci, L. Mannini, G. F. Gensini, R. Abbate

PP-TH-354 ACUTE ISCHEMIC CEREBROVASCULAR ACCIDENT (CVA) AFTER BEVACIZUMAB THERAPY. CASE REPORT & REVIEW OF THE LITERATURE
R. M. Biswar* (US), S. J. Jubelirer, J. G. Rosencrance

PP-TH-355 THE HPA-1B (PRO33) VARIANT OF PLATELET INTEGRIN ALPHAIIB BETA3 CAN INDUCE A PROTHROMBOTIC STATE
R. E. Scharf* (DE), V. R. Stoldt

PP-TH-356 A SYSTEMATIC REVIEW OF THE EFFECTS OF HEMOPHILIA AND VON WILLEBRAND DISEASE ON ARTERIAL TROMBOSIS
S. Rafi* (NL), M. Zwiers, M. Peters, J. van der Meer, F. R. Rosendaal, H. R. Buller, P. W. Kamphuisen

PP-TH-357 CHADS2 SCORE PREDICTION OF POST-OPERATIVE STROKE IN PATIENTS WITH AND WITHOUT ATRIAL FIBRILLATION
S. Kaatz* (US), B. F. Gage, J. D. Douketis, R. H. White

PP-TH-358 CLINICAL BACKGROUND OF ACUTE ISCHEMIC STROKE PATIENTS WITH EXTREMELY HIGH LEVEL OF SERUM D-DIMER
T. Nagao* (JP), A. Nogami, M. Okamura, N. Umesato, M. Inoue, M. Komine-Kobayashi, C. Nohara, N. Yoshimura, T. Ohtake, K. Hirabayashi, M. Yokochi, Y. Katayama, H. Takubo

PP-TH-359 COMPARISON OF TWO DIFFERENT HEPARIN DOSES IN PERIPHERAL VASCULAR SURGERY
U. Schott* (SE), D. Winstedt

PP-TH-360 GENETIC VARIATION IN THE PLASMA GLUTATHIONE PEROXIDASE (GPX-3) GENE IS ASSOCIATED WITH VASCULAR, BUT NOT THROMBOEMBOLIC, STROKE IN CHILDREN
U. Nowak-Gottl* (DE), S. Thedieck, T. Seehafer, M. Stoll

PP-TH-361 ACTIVATION OF HAEMOSTASIS IN ELDERLY PATIENTS WITH CHRONIC HEART FAILURE
V. M. Shmeleva* (RU), O. N. Semenova

PP-TH-362 TISSUE FACTOR PATHWAY INHIBITOR: A NEW LINK BETWEEN ARTERIAL STIFFNESS AND THROMBIN GENERATION
V. Regnault* (FR), A. Kearney-Schwartz, J. Max, T. Lecompte, A. Benetos, P. Lacolley

PP-TH-363 INFLAMMATION AND COAGULATION MARKERS IN HEART FAILURE PATIENTS: TRANSITION FROM ACUTE DECOMPENSATED TO CHRONIC HEART FAILURE
V. Vila* (ES), V. Martinez-Sales, I. Sanchez-Lazaro, L. Almenar, E. Reganon

PP-TH-364 CHARACTERIZATION OF CANDIDATE GENETIC DETERMINERS FOR MYOCARDIAL INFARCTION IN A GENETIC HOMOGENEOUS POPULATION
J. Cui, E. Randell, R. James, F. Y. Han, G. Sun, C. Butt, J. Hwa, Y. G. Xie* (CA)

PP-TH-365 RELATION BETWEEN CYTOCHROME P450 2C19 681 G>A POLYMORPHISM, PLATELET RESPONSIVENESS TO ADP AND CLINICAL OUTCOME AFTER ELECTIVE PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS TREATED WITH CLOPIDOGREL
C. Pouplard, E. Blicq, S. Regina, A. de Labriolle, B. Charbonnier, Y. Gruel* (FR)

PP-TH-366 INTERACTION BETWEEN HOMOCYSTEINE AND LIPOPROTEIN(A) INCREASES THE RISK OF CORONARY SCLEROSIS/MYOCARDIAL INFARCTION IN WOMEN
Z. Bereczky* (HU), É. Katona, E. Balogh, K. Kósa, I. Czuriga, I. Édes, L. Muszbek

 

PP-TH-367 ROLE OF NATURAL PROGESTERONE IN PROPHYLAXIS OF RECURRENT PREGNANCY LOSS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME
E. N. Shakhovskaya* (RU), A. D. Makatsaria

PP-TH-368 MONITORING OF HAEMOCOAGULATION CHANGES DURING LONG-TERM LOW MOLECULAR WEIGHT HEPARIN PROTECTION OF PREGNANCY
P. Sigutova* (CZ), Z. Hajsmanova, J. Slechtova, Z. Ulcova-Gallova

PP-TH-369 VENOUS THROMBOEMBOLISM IN CZECH WOMEN IN ASSOCIATION WITH ORAL CONTRACEPTIVE USE: FREQUENCY, ETIOLOGY AND THERAPY OF BUDD-CHIARI SYNDROME
P. Dulicek* (CZ), J. J. M. Mal?, T. T. F. Fejfar, R. R. M. Mal?, F. F. V. Vrback?

PP-TH-370 INTRAPARTUM BRIDGING THERAPY USING LOW MOLECULAR WEIGHT HEPARIN IN PREGNANT PATIENTS REQUIRING A HIGH DEGREE OF ANTICOAGULATION
R. S. Chitsike* (ZA), G. Toweel, S. Moodley, H. A. Rhemtula, P. Manga, B. F. Jacobson

PP-TH-371 IS DOSAGE ADJUSTMENT OF LOW MOLECULAR WEIGHT HEPARIN NECESSARY AND SAFE FOR PREGNANCIES AT GREATEST RISK OF THROMBOSIS
R. S. Chitsike* (ZA), H. A. Rhemtula, P. Manga, B. F. Jacobson

PP-TH-372 MODULATION OF COAGULATION FACTOR LEVELS AND THROMBIN GENERATION PARAMETERS BY A HEALTHY DIET IN PRE-MENOPAUSAL MIDDLE-AGED WOMEN WITH MODERATE CARDIOVASCULAR RISK
S. Calzavarini* (IT), S. Volpato, P. Caruso, A. Passaro, R. Fellin, F. Bernardi

PP-TH-373 PREVALENCE OF JAK2V617F MUTATION IN WOMEN WITH UNEXPLAINED RECURRENT MISCARRIAGE
S. P. Kaandorp, M. N. Lauw, C. van der Schoot, M. Goddijn, F. van der Veen, H. R. Koene, B. J. Biemond, S. Middeldorp* (NL)

PP-TH-374 PREVENTION OF VENOUS THROMBOEMBOLISM IN PREGNANT WOMEN: MANAGEMENT STRATEGY ON A LARGE HEALTH CARE AREA
S. Testa* (IT), O. Paoletti, E. Ronca, A. Rigolli, A. Alatri, A. Zimmermann, A. Riccardi

PP-TH-375 LOW MOLECULAR WEIGHT HEPARINS LABORATORY MONITORING: VARIABILITY IN RELATION TO CALIBRATION AND ANTITHROMBIN PLASMA LEVEL
S. Testa* (IT), O. Paoletti, L. Bassi, A. Alatri, A. Zimmermann, A. Cogrossi, M. Stramezzi

PP-TH-376 STRATEGY OF THROMBUS REMOVAL FOR ILIOFEMORAL DVT OF PREGNANCY
S. Thakur* (US), A. J. Comerota, J. L. Martinez Trabal, R. Disalle, S. N. Kazanjian, D. M. Sepanski, Z. Assi

PP-TH-377 CHANGES IN THE COAGULATION SYSTEM IN HUMANS AND MICE DURING PREGNANCY
S. N. Tchaikovski* (NL), B. van Vlijmen, M. L. G. D. Thomassen, E. Castoldi, L. L. Peeters, G. Tans, J. Rosing

PP-TH-378 ROLE OF THROMBOPHILIA IN PROSTHETIC VALVE THROMBOSIS DURING PREGNANCY
S. V. Akinshina* (RU), A. D. Makatsariya, V. O. Bitsadze, S. M. Baimuradova

PP-TH-379 PREGNANCY IN WOMEN WITH HISTORY OF STROKE: PATHOGENETIC PROPHYLAXIS IS POSSIBLE
S. V. Akinshina* (RU), A. D. Makatsariya, V. O. Bitsadze, S. M. Baimuradova

PP-TH-380 THROMBOPHILIC AND PROINFLAMMATORY STATES IN PREGNANT WOMEN WITH METABOLIC SYNDROME
T. B. Pshenichnikova* (RU), E. B. Perederyaeva, Z. Gadaeva, A. D. Makatsariya

PP-TH-381 MICROPARTICLES‘ PROCOAGULANT ACTIVITY AND SCD40L CONCENTRATION DURING PREGNANCY IN HEALTHY WOMEN AND WOMEN WITH ANTIPHOSPHOLIPID SYNDROME
M. Celinska-Lowenhoff, T. Iwaniec* (PL), A. Grzyb, J. Musial

PP-TH-382 INCREASED THROMBIN GENERATION DURING PREGNANCY
V. Rossetto* (IT), P. Dabrilli, L. Spiezia, M. Castelli, E. Campello, M. Perlati, S. Gavasso, P. Simioni

PP-TH-383 MILD RESISTANCE TO THROMBOPROPHYLAXIS WITH LMWH DURING PREGNANCY
V. Rossetto* (IT), P. Dabrilli, L. Spiezia, F. Dalla Valle, E. Campello, S. Gavasso, P. Simioni

PP-TH-384 ANTI-Xa MONITORING IS REQUIRED IN PREGNANT WOMEN ON LOW MOLECULAR WEIGHT HEPARIN (LMWH)
V. M. A. Simpson* (UK), M. Pescott, D. Peebles, H. Cohen

PP-TH-385 MANAGEMENT OF PREGNANCIES WITH HIGH RISK OF THROMBOSIS: A MULTIjustify PROSPECTIVE STUDY
Y. Dargaud* (FR), L. Rugeri, M. C. Vergnes, B. Arnuti, P. Miranda, C. Negrier, A. Bestion, H. Desmurs Clavel, J. Ninet, P. Gaucherand, C. R. Rudigoz, M. Berland, F. Champion, M. C. Trzeciak

PP-TH-386 ENDOGENOUS THROMBIN POTENTIAL, D DIMERS AND F 1+2 IN NORMAL PREGNANCY
Y. Dargaud* (FR), S. Hierso, L. Rugeri, B. Chatard, C. Battie, P. Gaucherand, C. Negrier

PP-TH-387 INVOLVEMENT OF HEPARANASE IN EARLY PREGNANCY LOSSES
Y. Nadir* (IL), I. Henig, I. Vlodavsky, B. Brenner

PP-TH-388 FACTOR XI ANTISENSE THERAPY REDUCES THROMBUS FORMATION IN MICE
E. C. Lowenberg* (NL), J. C. M. Meijers, H. Zhang, J. R. Crosby, E. S. Stroes, B. P. Monia, M. Levi

PP-TH-389 EXTENDED ADMINISTRATION OF DEFIBROTIDE IN NON-IMMUNOGENIC EXTENDED STUDIES IN RATS AND DOGS
J. Fareed* (US), D. Hoppensteadt, J. Cunanan, H. Zhu, C. Echart, M. Iacobelli

PP-TH-390 BIOAVAILABILITY OF OVER SULFATED CHONDROITIN SULFATE. IMMUNOLOGIC IMPLICATIONS
C. Adiguzel, D. Hoppensteadt, H. Messmore, J. M. Walenga, R. Wahi, J. Fareed* (US)

PP-TH-391 SUSTAINED ANTITHROMBOTIC ACTIVITY OF LMWHS COMPARED TO FXA INHIBITORS
J. M. Walenga* (US), W. P. Jeske, E. Litinas, J. Emanuele, D. Hoppensteadt, J. Cunanan, M. Bakhos

PP-TH-392 AUTOTAXIN/LYSOPHOSPHATIDIC ACID AXIS: IN VIVO EVIDENCE FOR A ROLE IN OBESITY PREDISPOSITION
L. Federico* (US), S. Liu, P. Muller, G. B. Mills, A. J. Morris, S. S. Smyth

PP-TH-393 THROMBOELASTOGRAPHIC (TEG) EVALUATION OF HEMOSTASIS IN A RAT MODEL OF OBSTRUCTIVE SLEEP APNEA
M. Othman* (CA), S. P. Gordon, S. Iscoe

PP-TH-394 EFFICACY AND SAFETY OF RFVIIa IN AN ACUTE ARTERIAL BLEEDING MODEL IN HEALTHY RABBIT: A BLIND STUDY
M. Durand* (FR), A. Godier, V. Notet, M. Hacquard, O. Collignon, G. Corbonnois, F. Plénat, J. P. Carteaux, T. Lecompte

PP-TH-395 THE INFLUENCE OF STREPTOKINASE ON PLATELET LINK OF HAEMOSTATIC SYSTEM
N. Burlova-Vasilieva* (UA), O. Savchuk, I. Krasnobrizha, G. Volkov

PP-TH-396 METHODS TO EVALUATE THE PHARMACOKINETICS OF TAL6003, A SIMPLIFIED VERSION OF PLASMIN
C. Cruz, K. Yarbrough, B. Sandy, P. Vandeberg* (US)

PP-TH-397 NEW INSIGHT INTO THE FUNCTION OF VKORC1L1
P. Westhofen* (DE), M. Watzka, M. Marinova, M. Hass, J. Oldenburg

PP-TH-398 PASSENGER GENE POINT MUTATION: DISCOVERY OF A SPONTANEOUS IRS1 MUTATION IN LINKAGE WITH PAI2 DEFICIENCY
R. J. Westrick* (US), K. L. Mohlke, G. Zhu, S. L. Manning, D. Ginsburg

PP-TH-399 EVALUATION OF ANTI HUMAN PLATELET GLYCOPROTEIN GPIIIA THERAPEUTIC CHIMERIC ANTIBODY F(AB)2 FRAGMENT IN BEAGLE DOGS
S. Ji* (CN), M. Jiang, Y. Zhao, W. Fang, J. Yang, C. Ruan

PP-TH-400 DEVELOPMENT AND EVALUATION OF AN IMMUNOASSAY FOR THE MONITORING OF A NEW ANTI-PLATELET DRUG CHIMERIC MONOCLONAL SZ21 F(AB)2
S. Ji* (CN), N. Wen, Z. Li, C. Ruan

PP-TH-401 FUNCTIONAL ROLES OF THROMBOXANE A2 ON PREECLAMPSIA
C. Pai, I. Yu, S. Lin, S. Lin* (TW)

PP-TH-402 A MILD ARTERIAL DAMAGE FACILITATES DOWNSTREAM THROMBUS FORMATION BY PRIMING PLATELET ACTIVATION
S. Momi* (IT), S. Giannini, P. Gresele

PP-TH-403 PRECLINICAL TOXICOLOGY AND SAFETY PHARMACOLOGY OF PLASMIN (HUMAN)
V. Arora* (US), G. A. Baumbach, P. Scuderi, S. R. Petteway

PP-TH-404 SALICYLAMIDE DERIVATIVES AS ANTAGONISTS FOR LOW MOLECULAR WEIGHT HEPARIN AND HEPARIN-LIKE DRUGS
C. Schroeder, M. Prechel, J. M. Walenga, W. P. Jeske* (US), M. Bakhos

PP-TH-405 EFFICACY OF ASPIRIN ON IMPROVEMENT OF PERIPHERAL BLOOD CIRCULATION IN MICE
W. K. Jeon* (KR), B. K. Yoo, B. S. Ko, J. Y. Ma

PP-TH-406 TREATMENT OF VENOUS THROMBOSIS WITH THE ORAL DIRECT FACTOR Xa INHIBITOR DU-176B IN CONSCIOUS RATS
Y. Morishima* (JP), Y. Honda, C. Kamisato-Matsumoto, T. Shibano

PP-TH-407 ATTENUATED ELEVATION OF SP-SELECTIN IN PATIENTS WITH RECENT MYOCARDIAL INFARCTION IS RELATED TO BLEEDING EVENTS DURING ANTITHROMBOTIC TREATMENT
C. Christersson* (SE), J. Oldgren, L. Wallentin, A. Siegbahn

PP-TH-408 GOAL-DIRECTED INTRAVENOUS HEPARIN (IVH) VERSUS SUBCUTANEOUS HEPARIN (SQH) IN PREVENTING THROMBOEMBOLISM IN POST-SURGICAL SICU PATIENTS
K. E. Nordenholz* (US), C. Hamiel, S. Cheng, A. Baer, D. Matero, N. Pearlman, P. Wischmeyer

PP-TH-409 CO-ADMINISTRATION OF IDRAPARINUX AND WARFARIN IN HEALTHY SUBJECTS
M. Trellu* (FR), I. Paty

PP-TH-410 EFFICACY AND SAFETY OF ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN JAPANESE PATIENTS UNDERGOING MAJOR ABDOMINAL SURGERY
M. Sakon* (JP)

PP-TH-411 CLINICAL EVALUATION OF FONDAPARINUX FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN JAPANESE PATIENTS UNDERGOING ABDOMINAL SURGERY
M. Sakon* (JP), T. Kobayashi

PP-TH-412 D-DIMER TO PREDICT THROMBOSIS RECURRENCE: COMPARISON OF AGGREGATE DATA AND INDIVIDUAL PATIENT DATA META-ANALYSES
M. Marcucci* (IT), A. Iorio, J. Douketis, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, A. Tosetto

PP-TH-413 ENOXAPARIN VERSUS DABIGATRAN ETEXILATE OR RIVAROXABAN FOR THROMBOPROPHYLAXIS AFTER HIP OR KNEE ARTHROPLASTY
M. V. Huisman* (NL), D. J. Quinlan, O. E. Dahl, S. Schulman

PP-TH-414 OPTIMAL MAINTENANCE OF AT ACTIVITY DURING HIGH-RISK SITUATIONS FOR THROMBOSIS WITH THE USE OF ANTITHROMBIN (RECOMBINANT)
M. J. Paidas* (US), C. Tait, J. Frieling

PP-TH-415 POTENTIAL IMPACT OF RIVAROXABAN ON LONG-TERM SAFETY OUTCOMES AFTER TOTAL HIP OR KNEE REPLACEMENT SURGERY
M. R. Lassen* (DK), A. G. G. Turpie, A. K. Kakkar, B. I. Eriksson, M. Gent

PP-TH-416 DECREASE OF INTRAOPERATIVE TRANSFUSION, ESPECIALLY FRESH FROZEN PLASMA, DURING CARDIOVASCULAR SURGERY LEADS TO DECREASE THE RISK OF THE POSTOPERATIVE INFECTION
M. Iwade* (JP), M. Nomura, K. Iwade

PP-TH-417 LACK OF EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HIGH-RISK PATIENTS UNDERGOING MAJOR ORTHOPEDIC OR MAJOR CANCER SURGERY: ELECTRONIC ASSESSMENT OF VTE PROPHYLAXIS IN HIGH-RISK SURGICAL PATIENTS AT DISCHARGE FROM SWISS HOSPITALS (ESSENTIAL)
N. Kucher* (CH), D. Spirk, K. Siebenrock, U. Metzger, D. Sterzing, M. Zuber, E. Mouhsine, C. Kalka

PP-TH-418 EVALUATION OF PERIPROCEDURAL ANTICOAGULATION MANAGEMENT IN PATIENTS ON LONG TERM ORAL ANTICOAGULANTS
N. Ostasevski Fernandez* (SI), A. Mavri

PP-TH-419 UNFRACTIONATED HEPARIN UFH VERSUS LOW MOLECULAR WEIGHT HEPARIN LMWH FOR BRIDGING DURING WARFARIN INTERRUPTION: A METAANALYSIS OF CONTROLLED CLINICAL TRIALS
O. Dabbagh* (US), M. P. Lent, S. R. Bearelly

PP-TH-420 PORTAL AND SPLANCNIC VEIN THROMBOSIS: STUDY ON RISK FACTORS AND TREATMENT ALGORITHM
M. T. Sartori, M. Senzolo, C. Ferronato, P. Burra, P. Boccagni, D. Gasparini, S. Gavasso, G. Saggiorato, P. Simioni* (IT)

PP-TH-421 PLATELET AGGREGATION AND ENDOGENOUS THROMBIN CAPACITY (ETC) ARE NOT INCREASED IN PATIENTS AFTER HEART TRANSPLANTATION
P. Staritz* (DE), A. Huth-Kühne, R. Zimmermann, T. J. Dengler, B. T. Ivandic

PP-TH-422 THE EFFECT OF VITAMIN K RICH DIET ON THE INR, VITAMIN K DEPENDENT FACTORS ACTIVITY, AND D-DIMER IN PATIENTS USING WARFARIN
P. Kessler* (CZ), M. Kusnierova, H. Poul, A. Komarek, E. Vlckova

PP-TH-423 PHARMACOKINETICS AND PHARMACODYNAMICS OF EP42675, A NEW SYNTHETIC ANTICOAGULANT WITH A DUAL MECHANISM OF ACTION
P. Gueret* (FR), C. Krezel, P. L. M. van Giersbergen, M. Petitou, E. Neuhart

PP-TH-424 PHYSICIAN ALERTS TO PREVENT SYMPTOMATIC VENOUS THROMBOEMBOLISM IN HOSPITALIZED PATIENTS
G. Piazza, E. J. Rosenbaum, W. Pendergast, J. O. Jacobson, R. C. Pendleton, G. D. McLaren, C. Elliott, S. M. Stevens, W. F. Patton, O. Dabbagh, M. D. Paterno, E. Catapane, S. Z. Goldhaber* (US)

PP-TH-425 THROMBOPROPHYLAXIS WITH CERTOPARIN IN ACUTELY ILL, NON-SURGICAL PATIENTS – CERTAIN STUDY
S. Schellong* (DE), S. Haas, A. Greinacher, C. Abletshauser, H. Riess

PP-TH-426 TOWARDS THE REDUCTION OF THE INCIDENCE OF MAJOR BLEEDING UNDER ANTICOAGULANT DRUGS IN MAJOR ORTHOPAEDIC SURGERY. MYTH OR REALITY
S. Laporte* (FR), P. Zufferey, P. Mismetti

PP-TH-427 LEFT VENTRICULAR (LV) THROMBUS FORMATION IN SPITE OF INTENSIVE ANTIPLATELET TREATMENT IN PATIENTS WITH ACUTE ANTERIOR WALL ST ELEVATION MYOCARDIAL INFARCTION (STEMI) TREATED WITH PCI
S. Solheim* (NO), I. Seljeflot, K. Lunde, R. Bjørnerheim, S. Aakhus, K. Forfang, H. Arnesen

PP-TH-428 COMPARISON OF TWO INFUSIONRATES OF ANTITHROMBIN CONCENTRATE IN CARDIOPULMONARY BYPASS SURGERY
U. Schott* (SE), T. Carlsson, P. Lund

PP-TH-429 THE INFLUENCE OF GENETIC BESIDES NON GENETIC FACTORS ON WARFARIN RESPONSE IN 300 VERY ELDERLY INPATIENTS
V. Siguret* (FR), C. Moreau, I. Gouin-Thibault, J. L. Golmard, I. Mahe, P. Beaune, E. Pautas, M. A. Loriot

PP-TH-430 BLEEDING EVENTS IN THE EARLY PHASE OF THROMBOPROPHYLAXIS: A POOLED ANALYSIS OF FOUR RIVAROXABAN STUDIES
W. D. Fisher* (CA), M. R. Lassen, A. G. G. Turpie, A. K. Kakkar, B. I. Eriksson, M. Gent

PP-TH-431 THE GENETIC PREDICTORS OF BLEEDINGS DURING WARAFRIN THERAPY (THE DATA BASED ON FIVE YEAR PROSPECTIVE STUDY
Y. A. Mikheeva* (RU), E. S. Kropacheva, D. A. Sichev, A. B. Dobrovolsky, E. P. Panchenko

PP-TH-432 HAEMOSTATIC PARAMETERS IN PATIENTS WITH SUBCLAVIAN CATHETERASSOCIATED THROMBOSIS
L. Petit, V. Cottenceau, F. Masson, S. Labrouche, G. Freyburger* (FR)

PP-TH-433 INFLAMMATORY AND COAGULATION MARKERS IN PATIENTS WITH ATRIAL FIBRILATION TREATED WITH RF ABLATION
J. Kyselovic* (SK), P. Musil, L. Urban, P. Krenek, R. Hatala

PP-TH-434 COAGULATION LABORATORY SCREENING IS NOT A GOOD PREDICTOR FOR BLEEDING COMPLICATIONS IN PEDIATRIC PATIENTS REQUIRING PERIPHERALLY INSERTED CENTRAL CATHETERS
J. Woodley-Cook* (CA), J. Amaral, B. Connolly, L. Brandao

PP-TH-435 BIOMATERIAL SURFACE MODIFICATION WITH AN ANTITHROMBIN-HEPARIN COVALENT COMPLEX FOR IMPROVED INTRAVASCULAR DEVICES
K. N. Sask* (CA), J. L. Brash, A. K. C. Chan, L. R. Berry, W. G. McClung

PP-TH-436 TROMBIN GENERATION AS HEMOSTASIS INDICATOR: VALIDATION IN A CVVH SETTING
M. van Schilfgaarde* (NL), H. M. Oudemans,van Straaten, P. J. Molenaar, N. R. Wiertz, J. P. J. Wester, A. Leyte

PP-TH-437 PREDICTIVE VALUE OF COAGULATION MARKER (D-DIMER) AND PLASMA MARKERS OF MYOCARDIAL DAMAGE ON SUCCESS RATE OF RADIOFREQUENCY ABLATION OF ATRIAL FIBRILLATION
P. Musil* (SK), J. Kyselovic, P. Krenek, L. Urban, R. Hatala

PP-TH-438 TREATMENT OF ILEOFEMORAL DEEP VEIN THROMBOSIS IN PUERPERIUM USING CATHETER-DIRECTED THROMBOLYSIS
R. Maly* (CZ), V. Chovanec, A. Krajina, J. Raupach, M. Lojik, P. Dulicek, L. Vodickova, M. Solar, J. Fridrich, J. Vojacek

PP-TH-439 IN VITRO EVALUATION OF ARTIFICIAL MEMBRANE BIOCOMPATIBILITY
S. C. Minkin* (US), M. Benner, M. Beeler, B. Curry, P. Iakova, J. Biggerstaff, P. Cahalan, L. Cahalan

PP-TH-440 EFFICACY OF ENOXAPARIN, CERTOPARIN, AND DALTEPARIN IN PREVENTING CARDIAC CATHETER THROMBOSIS: AN IN VITRO APPROACH
U. Raaz* (DE), M. Buerke, M. Busshardt, L. Maegdefessel, A. Plehn, B. Hauroeder, K. Werdan, A. Schlitt

PP-TH-441 EXPERIENCE OF TREATING PEDIATRIC VENOUS THROMBOEMBOLISM WITH LOW MOLECULAR WEIGHT HEPARIN (LMWH) IN AN INSTITUTE LACK OF ANTI-Xa MONITORING SUPPORT
J. Y. K. Yang* Hong Kong Special Administrative Region of (CN), M. L. G. Wong, A. K. C. Chan, R. C. H. Li, A. C. W. Lee

PP-TH-442 COMPLIANCE OF ANTITHROMBOTIC MANAGEMENT WITH PAEDIATRIC GUIDELINES
F. H. Newall, J. Doan* (AU), T. Wallace, V. Ignjatovic, P. Monagle

PP-TH-443 PLATELET AGGREGATES AND LEUCOCYTES IN THE LUNG CAPILLARIES OF CASES OF SUDDEN INFANT DEATH SYNDROME
L. Jørgensen* (NO), T. Hanssen

PP-TH-444 CEREBRAL VENOUS THROMBOSIS IN CHILDREN: EVALUATION OF THE ASSOCIATION WITH PROTHROMBOTIC RISK FACTORS
L. R. Goncalves* (PT), M. Carvalho, M. M. Campos, R. Vaz, L. M. Ribeiro

PP-TH-445 HIGHER ENDOGENOUS THROMBIN POTENTIAL VALUE AS PROTHROMBOTIC MARKER IN NEWLY DIAGNOSED PEDIATRIC CANCER PATIENTS
M. Aly Aldeen Abd Elbasset Aly Mohamed* (EG), R. M. Edwards, D. Cooper, I. Tjia, M. Hesham, U. Roshdy Elsafy, M. Badr, L. Bomgaars, A. Pappo, M. Chintagumpala, J. Teruya

PP-TH-446 OUTCOME OF CATHETER-RELATED ARTERIAL THROMBOSIS IN CHILDREN
S. Kroiss, O. Kretschmar, I. Forster, M. Schmugge, M. Albisetti* (CH)

PP-TH-447 THE RATIO ACTIVITY/ANTIGENIC LEVEL OF SOLUBLE THROMBOMODULIN AS A MARKER OF VASCULAR INJURY IN CHILDHOOD BONE MARROW TRANSPLANTATION
A. Rousseau, P. Schneider, P. van Dreden, J. P. Vannier, M. Vasse* (FR)

PP-TH-448 INHIBITION OF THROMBIN GENERATION BY RIVAROXABAN IN NEONATAL PLASMA
M. Novak* (AT), H. Bernhard, M. Koestenberger, D. Ulrich, B. Leschnik, S. Schweintzger, W. Muntean

PP-TH-449 PROPHYLAXIS FOR SEVERE PROTEIN C DEFICIENCY: A NOVEL APPROACH
M. D. Williams* (UK), D. Marshall, P. Nyatanga

PP-TH-450 RECURRENT PULMONARY EMBOLISM IN A 14 YEAR OLD BOY WITH ANTIPHOSPHOLIPID SYNDROME
M. Girisch* (DE), R. Rauch, G. Wiegand, M. Hofbeck

PP-TH-451 CEREBRAL THROMBOEMBOLISM IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
N. Conde, N. Conde* (ES), T. Toll, R. Berrueco, A. Català, S. Rives, J. Estella

PP-TH-452 OUTCOME AFTER CENTRAL VENOUS LINES RELATED VENOUS THROMBOSIS (CVLVT) IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A SINGLE CENTRE PROSPECTIVE STUDY
P. Saracco* (IT), L. L. Garbarini, N. N. Bertorello, E. E. Barisone, S. S. Longo, L. L. Artesani, L. L. Farinasso

PP-TH-453 A RETROSPECTIVE AND PROSPECTIVE SINGLE CENTRE STUDY ON APPLICABILITY OF THE PROPOSED WRAIGE CLASSIFICATION FOR SUBTYPES OF ARTERIAL ISCHEMIC STROKE (AIS) IN CHILDREN
P. Saracco* (IT), M. Agostini, A. Tocchet, R. Vittorini, V. Licari, C. Marinaccio, L. Pagana, B. Bobba, B. Bassi

PP-TH-454 FACTORS OF EXTRACEREBRAL NON CATHETHER RELATED THROMBOSIS IN CHILDREN
P. V. Svirin* (RU), V. V. Vdovin, G. A. Sukchanova, T. G. Plachuta, L. E. Larina, E. A. Shiller, E. A. Yatzenko, A. V. Ageenkova, E. K. Doniusch

PP-TH-455 VALIDITY OF PAEDIATRIC THROMBOSIS DIAGNOSES IN A NATIONAL REGISTRY OF PATIENTS
R. Tuckuviene* (DK), J. Helgestad, S. P. Johnsen, S. R. Kristensen

PP-TH-456 INHERITED THROMBOPHILIA IN CHILDHOOD STROKE: EXPERIENCE OF A TERTIARY CARE justify IN LEBANON
S. A. Muwakkit* (LB), M. Majdalani, R. Hourani, Z. Otrock, R. Saab, M. Abboud, M. Mikati

PP-TH-457 MANAGEMENT OF VENOUS THROMBOEMBOLIC EVENTS IN PEDIATRIC ICU PATIENTS
S. J. Hanson* (US), K. A. Lawson, A. Brown, L. M. Christie, B. Totapally, J. McArthur, R. A. Higgerson

PP-TH-458 EFFECTIVENESS AND LONG-TERM OUTCOME OF THE USE OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (RT-PA) IN CHILDREN WITH LIFE-THREATENING THROMBOSIS
S. J. Russell* (AU), G. D. Williams, J. J. Brereton, A. Numa

PP-TH-459 EQUIVALENCY OF TINZAPARIN AND ENOXAPARIN CHILDREN: A SINGLE CENTRE REPORT ON EFFICACY AND SAFETY
A. Al-Zahrani* (SA), P. Komwilaisak, L. Brandao, W. H. A. Kahr, A. K. C. Chan, S. Williams

PP-TH-460 PROTHROMBOTIC GENETIC RISK FACTORS IN STROKE: A POSSIBLE DIFFERENT ROLE IN PEDIATRIC AND ADULT PATIENTS
V. J. Djordjevic* (RS), M. Stankovic, V. Brankovic-Sreckovic, L. Rakicevic, T. Damnjanovic, N. Antonijevic, D. Radojkovic

PP-TH-461 LOW MOLECULAR WEIGHT HEPARIN (LMWH) RESPONSE IN CHILDREN
V. Ignjatovic* (AU), C. Cuman, R. Summerhayes, F. Newall, P. Monagle

PP-TH-462 AGE-RELATED DIFFERENCES IN THE BINDING OF UNFRACTIONATED HEPARIN (UFH) TO PLASMA PROTEINS
E. Straka, V. Ignjatovic* (AU), R. Summerhayes, P. Monagle

PP-TH-463 EXTENSIVE CEREBRAL SINUS VENOUS THROMBOSIS IN THE SETTING OF HYPERTHYROIDISM IN A CHILD
V. F. van Eimeren* (CA), L. Billinghurst, E. Yiu, R. Askalan, T. Soman, S. Laughlin, L. R. Brandão, S. Williams, W. H. A. Kahr

PP-TH-464 A 4-YEAR FOLLOW-UP OF ADVERSE EFFECTS WITH FONDAPARINUX TREATMENT: RESULTS FROM THE FRENCH PHARMACOVIGILANCE SURVEY
A. Lillo-Le Louet, D. M. Smadja* (FR), C. Le Beller

PP-TH-465 THROMBOPHILIA TESTING - A COMPARATIVE STUDY
L. Mammo, T. Saour, A. Sheereen, J. Saour* (SA)

PP-TH-466 RARE VKORC1 MUTATIONS IN AFRICAN BRAZILIAN PATIENTS TAKING ORAL ANTICOAGULANT THERAPY
F. A. Orsi, K. Weck, E. V. de Paula, J. Evans, M. C. Ozelo, J. M. Annichino-Bizzacchi* (BR)

PP-TH-467 MONITORING OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) THERAPY BY ANTI-Xa ASSAY. A LABORATORY PERSPECTIVE USING HEPARIN SPECIFIC STANDARDS
P. A. Kotsi* (GR), A. Chanos, I. Anastasopoulou, C. Tsoukala, K. Markakis, A. Karafoulidou

PP-TH-468 EVALUATION OF OPTIMAL SAMPLING METHODS FOR MICROPARTICLES IN STORED RED BLOOD CELLS
P. Davizon-Castillo* (US), J. A. Lopez, T. R. Watkins

PP-TH-469 TIR - RESULTS FROM THE NATIONAL QUALITY REGISTRY FOR ANTICOAGULATION TREATMENT IN SWEDEN
P. J. Svensson* (SE), V. Frykman, A. Själander, M. Rosenqvist, L. Wallentin

PP-TH-470 ARE CITRATED PARTIAL-DRAW POLYMER COLLECTION TUBES ADEQUATE FOR BASIC COAGULATION TESTS
P. A. Toulon* (FR), V. Eschvege, M. Dreyfus, T. Boutekedjiret, V. Proulle

PP-TH-471 A VTE PREVENTION PROGRAM IMPLEMENTED BY A VTE NURSE SPECIALIST LEADS TO A MARKED AND SUSTAINED IMPROVEMENT IN APPROPRIATE VTE PROPHYLAXIS
R. D. Collins* (AU), H. Gibbs, J. Gibbs, J. Schluter, L. Tewhatu

PP-TH-472 SIGNIFICANT IMPROVEMENT OF VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS IN A TERTIARY REFERRAL HOSPITAL DOES NOT LEAD TO AN INCREASE IN INAPPROPRIATE VTE PROPHYLAXIS IN PATIENTS NOT AT RISK
R. D. Collins* (AU), H. Gibbs, J. Gibbs, J. Schluter, L. Tewhatu

PP-TH-473 PRECISION AND ACCURACY STUDY OF A TABLE TOP COAGULATION ANALYZER WITH EXPANDED TEST MENU
R. Porche-Sorbet* (US), J. Hughes, P. Barnes, G. Cutsforth, K. Whelchel, C. S. Eby

PP-TH-474 ASSESSMENT OF QUALITY CONTROL AND ACCURACY OF PORTABLE COAGULOMETERS FOR MONITORING ORAL ANTICOAGULANT TREATMENT IN ANTICOAGULATION CLINIC
R. Paniccia* (IT), D. Poli, E. Antonucci, M. Pagliuca, D. Lami, I. Ricci, A. Alessandrello Liotta, D. Prisco, R. Abbate

PP-TH-475 AUTOMATED ANTI-FACTOR IIA ASSAY FOR MONITORING UNFRACTIONATED HEPARIN (UFH)
R. Summerhayes* (AU), V. Ignjatovic, F. Newall, P. Monagle

PP-TH-476 MEASURES TO IMPROVE SAFETY OF WARFARINIZED PATIENTS FOLLOWING HOSPITAL DISCHARGE
S. R. Hossain* (UK), M. Madhani, G. Varma, P. K. MacCallum

PP-TH-477 A RETROSPECTIVE REVIEW OF BIDGING THERAPY IN A COMMUNITY BASED OUT PATIENT ANTICOAGULATION CLINIC
S. Beaudoin* (US), S. C. Johnson, M. Mukon, D. Kapur, M. Dhami, D. E. Slater

PP-TH-478 EVALUATION OF COMPLIANCE WITH LOW DOSE UNFRACTIONATED HEPARIN FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN MEDICALLY ILL HOSPITALIZED PATIENTS AT AN ACADEMIC MEDICAL
S. H. Bhatt* (US)

PP-TH-479 HEMOPHILIA IN UKRAINE:PROBLEMS AND PROSPECTS
S. V. Vydyborets* (UA), G. I. Moroz, S. M. Gaydukova

PP-TH-480 OUTPATIENT DVT TREATMENT – AN AUDIT OF SAFETY INDICATORS FOR PATIENTS ON ORAL ANTICOAGULANT TREATMENT
S. Bacon* (UK), S. Chadwick

PP-TH-481 PHARMACOGENETIC RELEVANCE OF CYP4F2 V433M POLYMORPHISM ON ACENOCOUMAROL THERAPY
V. Pérez Andreu* (ES), V. Roldan, A. Anton, N. Garcia Barbera, J. Corral, V. Vicente, R. Gonzalez Conejero

PP-TH-482 A PROSPECTIVE ANALYSIS OF PLASMA TISSUE FACTOR IN PATIENTS WITH OVARIAN TUMORS
A. Amirkhosravi* (US), G. Bigsby Iv, E. Coll, H. Desai, M. Amaya, L. Robles, P. Faust, A. Drexler, F. Langer, E. Reyes, J. Francis

PP-TH-483 VENOUS THROMBOEMBOLISM DURING THE COURSE OF PANCREATIC CANCER: IMPLICATION OF TISSUE FACTOR
A. Delluc* (FR), A. Rousseau, C. Delluc, E. Le Moigne, G. Le Gal, K. Lacut, E. Oger, P. van Dreden, D. Mottier

PP-TH-484 METASTASIS PROMOTING EFFECTS OF DIRECT THROMBIN INHIBITORS
T. M. H. Niers, G. L. van Sluis* (NL), L. W. Bruggeman, R. D. Liu, H. H. Versteeg, H. R. Buller, C. J. F. van Noorden, P. H. Reitsma, C. A. Spek, D. J. Richel

PP-TH-485 CANCER CELLS ACCELERATE IN VITRO THROMBIN GENERATION IN HUMAN PLASMA BUT THEIR EFFECT IS DETERMINED BY THE HISTOLOGICAL TYPE OF THE CANCER
G. T. Gerotziafas* (FR), V. Galea, E. Mbemba, A. Khaterchi, F. Couppey, C. Prengel, M. Hatmi, J. Bernaudin, I. Elalamy

PP-TH-486 CLINICALLY RELEVANT CONCENTRATIONS OF FONDAPARINUX EFFICIENTLY INHIBIT IN VITRO THROMBIN GENERATION TRIGGERED BY DIFFERENT HISTOLOGICAL TYPES OF CANCER CELLS
G. T. Gerotziafas* (FR), V. Galea, E. Mbemba, A. Khaterchi, C. Prengel, M. Hatmi, J. Bernaudin, I. Elalamy

PP-TH-487 PROCOAGULANT PHOSPHOLIPIDS IN PATIENTS WITH VENOUS THROMBOEMBOLISM AND CANCER
L. Spiezia* (IT), E. Campello, S. Gavasso, V. Rossetto, C. Abalotti, B. Woodhams, P. Simioni

PP-TH-488 HYPOFIBRINOLYSIS IN PATIENTS WITH VENOUS THROMBOEMBOLISM AND CANCER
L. Spiezia* (IT), E. Campello, S. Gavasso, V. Rossetto, F. Dalla Valle, S. Barbar, B. Woodhams, P. Simioni

PP-TH-489 DOSE ESCALATION OF LOW MOLECULAR WEIGHT HEPARIN TO MANAGE RECURRENT VENOUS THROMBOEMBLIC EVENTS DESPITE SYSTEMIC ANTICOAGULATION IN CANCER PATIENTS
M. Carrier* (CA), G. Le Gal, R. Cho, S. Tierney, M. A. Rodger, A. Y. Lee

PP-TH-490 D-DIMER AS A POSSIBLE PROGNOSTIC MARKER OF BREAST CANCER IN HORMONAL RECEPTOR NEGATIVE PATIENTS
M. G. Carvalho* (BR), A. P. Fernandes, C. P. Figueiredo, E. C. Bueno, M. A. Ribeiro, K. B. Gomes, L. M. S. Dusse, A. P. B. Batschauer

PP-TH-491 TUMOR CELL-DERIVED MICROPARTICLES: DOES SIZE MATTER
M. Davila* (US), A. Amirkhosravi, C. H. Baker, J. Colon, J. Francis

PP-TH-492 LACK OF PROPHYLAXIS PRIOR TO THE ONSET OF ACUTE VENOUS THROMBOEMBOLISM AMONG HOSPITALIZED CANCER PATIENTS
N. Kucher* (CH), D. Spirk, C. Kalka, L. Mazzolai, D. Nobel, M. Banyai, B. Frauchiger, H. Bounameaux

PP-TH-493 MAGNETIC RESONANCE IMAGING: IS IT USEFUL FOR DIAGNOSIS OF ASYMPTOMATIC CEREBRAL THROMBOEMBOLIC EVENTS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA
P. Giordano* (IT), M. Grassi, V. Cecinati, G. C. Del Vecchio, F. Dicuonzo, M. Palma, G. Arcamone, N. Santoro, D. de Mattia

PP-TH-494 PROGNOSTIC VALUE OF THROMBOPATH DETERMINATION FOR CHEMOTHERAPYASSOCIATED VENOUS THROMBOEMBOLISM
P. Ferroni* (IT), F. Martini, I. Portarena, I. Grenga, S. Riondino, A. Spila, R. D’Alessandro, M.
G. Pera, A. Laudisi, M. Roselli, F. Guadagni

PP-TH-495 KUNITZ TYPE INHIBITOR (RKTI) INDUCES CHANGES IN GENE EXPRESSION, PROTEASOME INHIBITION AND APOPTOSIS IN CANCER CELLS
P. L. De-Sá-Júnior* (BR), E. M. Reis, S. A. Barreto, E. M. Akagi, S. M. Simons, M. Demasi, A. M. Chudzinski-Tavassi

PP-TH-496 DEEP VEIN THROMBOSIS – WHAT LIES BENEATH
P. Braude* (UK), B. Prathibha

PP-TH-497 STANDARDS, OPTIONS : RECOMMENDATIONS 2008 PROPHYLAXIS AND TREATMENT OF CENTRAL VENOUS CATHETER THROMBOSIS IN CANCER PATIENTS
P. Debourdeau* (FR), D. Kassab Chahmi, E. Desruennes, M. Douard, I. Kriegel, A. Elias, I. Elalamy, G. Legal, M. Pavic, M. Scroboachi, I. Quere, D. Farge Bancel

PP-TH-498 THE INCIDENCE OF VENOUS THROMBOEMBOLISM AND ITS IMPACT ON SURVIVAL IN PATIENTS WITH BLADDER CANCER
R. K. Sandhu* (US), R. H. White, T. Wun, H. K. Chew

PP-TH-499 PROCOAGULANT PROPERTIES OF MELANOMA MICROVESICLES SUGGEST THEIR INVOLVEMENT IN CANCER-ASSOCIATED THROMBOSIS
R. Q. Monteiro* (BR), R. Chammas, C. P. Vicente, M. A. Barcinski, L. G. Lima

PP-TH-500 HAEMOSTATIC AND HAEMORHEOLOGICAL CHANGES IN AFRICAN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
S. O. Abegunde* (NG), A. A. Famodu, O. A. Awodu, I. O. Ajayi, F. A. Ojeokun

PP-TH-501 HAEMOSTATIC AND HAEMORHEOLOGICAL CHANGES IN AFRICAN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA
S. O. Abegunde* (NG), A. A. Famodu, O. A. Awodu, I. O. Ajayi, F. A. Ojeokun

PP-TH-502 THE ROLE OF TISSUE FACTOR-FACTOR VIIa-PROTEASE ACTIVATED RECEPTOR 2 SIGNALING IN BREAST CANCER PROGRESSION
T. McEachron* (US), F. Church, N. Mackman

PP-TH-503 DECREASED OVERALL SURVIVAL AND INCREASED RISK OF THROMBOSIS IN CHILDREN WITH CANCER AND CENTRAL VENOUS LINE (CVL) DYSFUNCTION
U. Athale* (CA), S. Siciliano, J. Cheng, L. Thabane, A. K. C. Chan

PP-TH-504 LOW INCIDENCE OF THROMBOEMBOLISM IN KOREAN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH THALIDOMIDE
Y. Koh* (KR), S. Bang, J. Lee, H. Yoon, Y. Do, H. Ryoo, N. Lee, S. Kim, K. Kim, H. Kim, S. Yoon, J. Won, Y. Mun, M. Lee, K. Rhee, H. Eom, M. Kim, H. Shin

PP-TH-505 DIAGNOSTIC PERFORMANCE OF THE VIDAS D-DIMER IN A PROSPECTIVE STUDY OF INPATIENTS AND EMERGENCY PATIENTS EVALUATED FOR PULMONARY EMBOLISM WITH ANALYSIS OF PERCENT OBSTRUCTION
D. M. Courtney* (US), N. T. Klekowski, C. D. Miller, H. A. Smithline, M. M. Hogg, J. A. Kline

PP-TH-506 THROMBOPHILIC RISK FACTORS IN PATIENTS UNDERGOING MAJOR ABDOMINAL SURGERY AND THEIR RELEVANCE TO DEEP VENOUS THROMBOSIS
E. A. A. Khaled* (EG), F. M. Essawy, E. M. Esmat, N. A. Hussein, S. E. Sabaie, A. S. Hassanien, N. E. Mikhail

PP-TH-507 AGREEMENT OF PERFUSION SCINTIGRAPHY AND CT-ANGIOGRAPHY IN DETECTING RESIDUAL THROMBOEMBOLI AFTER PULMONARY EMBOLISM
F. Dentali* (IT), M. Donadini, B. Cosmi, S. Bozzato, A. Squizzato, C. Neri, W. Ageno

PP-TH-508 DIAGNOSIS OF DEEP VEIN THROMBOSIS BY COMPRESSION ULTRASONOGRAPHY DURING PREGNANCY AND THE POSTPARTUM PERIOD: A MANAGEMENT OUTCOME STUDY
G. Le Gal* (FR), M. Righini, G. Kercret, L. Bressollette, P. Louis, C. Bohec, M. Labalette, D. Mottier, ANGIO-GETBO Group

PP-TH-509 EVALUATION OF THE INNOVANCE® D-DIMER ASSAY ON THE SYSMEX® CA-7000 SYSTEM
S. Park, H. Chi* (KR), S. Chun, S. Jang, C. Park

PP-TH-510 PROSPECTIVE AUDIT OF THE MEDICAL DOCUMENTATION AND OUTCOMES OF PATIENTS EVALUATED WITH THE PULMONARY EMBOLISM RULE-OUT CRITERIA
J. A. Kline* (US), C. Peterson, M. T. Steuerwald

PP-TH-511 RESULTS OF A MULTIjustify, CROSS-SECTIONAL VENOUS THROMBOSIS SCREENING STUDY IN IZMIR
M. Karacelik* (TR), E. Kara, I. Erdinc, A. B. Ozelci, C. S. Atalay, E. O∂uz, M. Sen, G. Albayrak, S. T. Kutlu, E. Bahtiyar, C. Sert, A. Gurbuz, T. Calkavur, Karabay

PP-TH-512 ROLE OF CONGENITAL THROMBOPHILIC CONDITIONS IN THE DEVELOPMENT OF THROMBUS FLOTATION
N. A. Vorobyeva* (RU), M. G. Anisimov

PP-TH-513 LEVEL OF D-DIMER AND DURATION OF SYMPTOMS OF VENOUS THROMBOEMBOLISM
N. M. Vorobyeva* (RU), E. P. Panchenko, A. B. Dobrovolsky, E. V. Titaeva, A. I. Kirienko

PP-TH-514 FATAL PULMONARY EMBOLISM IN YOUNG PEOPLE: RISK FACTORS AND CLINICAL PRES-ENTATION
O. V. Fesenko* (RU), A. V. Glechikov

PP-TH-515 VALIDATION OF 9 DIFFERENT PROTEIN S ASSAYS IN A FAMILY COHORT WITH A PROS1 MUTATION
R. Mulder* (NL), M. K. ten Kate, A. B. Mulder, H. C. Kluin-Nelemans, J. van der Meer

PP-TH-516 CALIBRATED AUTOMATED THROMBOGRAPHY IN THE PRESENCE AND ABSENCE OF THROMBOMODULIN TO ASSESS THE PROTHROMBOTIC STATE
R. Mulder* (NL), M. K. ten Kate, H. M. H. Spronk, R. van Oerle, H. ten Cate, A. B. Mulder, H. C. Kluin-Nelemans, J. van der Meer

PP-TH-517 COMPARISON OF 4- AND 64-SLICE CT SCANNING IN THE DIAGNOSIS OF PULMONARY EMBOLISM
R. A. Douma* (NL), H. M. A. Hofstee, C. Schaefer-Prokop, J. H. T. M. van Waesberghe, R. Lely, P. W. Kamphuisen, V. E. A. Gerdes, M. H. H. Kramer, H. R. Büller

PP-TH-518 AGE-ADJUSTED D-DIMER CUT-OFF LEVELS INCREASE THE CLINICAL UTILITY OF RULING OUT PULMONARY EMBOLISM IN ELDERLY PATIENTS
R. A. Douma* (NL), G. Le Gal, M. Söhne, M. Righini, P. W. Kamphuisen, A. Perrier, M. J. H. A. Kruip, H. Bounameaux, H. R. Büller, P. M. Roy

PP-TH-519 UTILITY OF D-DIMER ASSAY FOR DIAGNOSING PULMONARY EMBOLISM: SINGLE INSTITUTE STUDY
R. Park* (KR), Y. Seo, S. Yoon, J. Shin, T. Choi, S. Lee, S. Uh, Y. Kim

PP-TH-520 NEW AUTOMATED CHEMILUMINESCENT D-DIMER IMMUNOASSAY: ANALYTICAL AND CLINICAL PERFORMANCE IN PATIENTS SUSPECTED OF VTE
R. G. Barry* (US), J. F. Guasch, Z. Pascual, J. Serra, K. A. Morin, J. Arnout, M. Vanrusselt, P. de Moerloose, G. Reber

PP-TH-521 D-DIMER TEST FOR DIAGNOSIS OF DEEP VENOUS THROMBOSIS (DVT) IN THE ICU
R. Moroi* (JP), A. Yaguchi, M. Takeda, M. Abe, T. Harada, T. Yamaki

PP-TH-522 DEVELOPMENT OF A CLINICAL CUT-POINT FOR A NEW AUTOMATED D-DIMER
S. M. Bates* (CA), M. Johnston, E. Ali, J. S. Ginsberg

PP-TH-523 RETROSPECTIVE EVALUATION OF AN IMMUNOTURBIDOMETRIC D-DIMER ASSAY AS A STAND-ALONE TEST TO EXCLUDE VENOUS THROMBOEMBOLISM
S. M. Bates* (CA), M. Johnston, E. Ali, J. S. Ginsberg

PP-TH-524 INTEROBSERVER REPRODUCIBILITY OF CLINICAL PROBABILITY ASSESSMENT IN SUSPECTED PULMONARY EMBOLISM: REVISED GENEVA SCORE AND WELLS SCORE
S. Dambrine* (FR), F. Verschuren, G. Le Gal, J. Callahan, N. Delvau, C. Coroller-Bec, M. Righini, D. Aujesky, O. Sanchez, A. Perrier, F. Thys, P. Roy

PP-TH-525 OUTCOME OF 205 VTE PATIENTS, PATICULAR REFERENCE TO NATIONAL PATIENT SAFETY ALERT 18 - SAFER ANTICOAGULATION
S. B. Bacon* (UK), S. Chadwick

PP-TH-526 ELEVATED LEVELS OF SOLUBLE FIBRIN IN PATIENTS WITH VENOUS THROMBOEMBOLISM
T. Matsumoto* (JP), H. Wada, A. Tsuji, S. Ota, N. Yamada, T. Sugiyama, K. Ohishi, A. Sudo, Y. Abe, N. Ito, K. Onishi, K. Nakatani, A. Uchida, K. Suzuki, M. Ito, N. Katayama, T. Nobori

PP-TH-527 VENOUS THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH SEVERE COAGULOPATHY UNDERGOING MAJOR SURGERY
A. Malato* (IT), A. Tagliaferri, P. Redossi, P. Solimeno, G. Saccullo, L. Lo Coco, G. Tagariello, S. M. Siragusa

PP-TH-528 USE OF A COMMERCIAL FVIII ANTIBODY SCREEN ELISA
A. F. Riddell* (UK), S. Brooks, T. Yee

PP-TH-529 THE INTERACTIONS OF A NEW RFVIII (N8) WITH VWF AND LRP
I. Hilden* (DK), E. Persson

PP-TH-530 TWENTY YEARS OF IMPROVEMENT IN THE TREATMENT OF CHILDREN WITH HAEMOPHILIA IN THE CZECH REPUBLIC
J. Blatny* (CZ), O. Zapletal, V. Komrska

PP-TH-531 DOSING AND SAFETY OF ANTITHROMBIN CONCENTRATE IN PEDIATRIC PATIENTS WHO REQUIRE HEPARIN ANTICOAGULATION
M. E. Bauman* (CA), K. L. Black, A. Bruce, S. Kuhle, L. Bajzar, M. P. Massicotte

PP-TH-532 SPONTANEOUS CERVICAL EPIDURAL HAEMATOMA IN HAEMOPHILIA: AN IMPORTANT DIFFERENTIAL DIAGNOSIS OF UNSPECIFIC BACK PAIN
M. S. Pereira* (BR), G. C. Duarte, E. V. de Paula, F. A. Orsi, M. C. Ozelo, J. M. Annichino-Bizzachi

PP-TH-533 MAGNETIC RESONANCE IMAGING (MRI) IDENTIFIES EARLIEST JOINT DAMAGE IN CLINICALLY ASYMPTOMATIC PATIENTS WITH HEMOPHILIA A, HEMOPHILIA B AND VON WILLEBRAND DISEASE DESPITE PROPHYLAXIS
M. Olivieri* (DE), C. Bidlingmaier, K. Kurnik

PP-TH-534 THE IMPACT OF INHIBITORS ON THE COST OF CLOTTING FACTOR REPLACEMENT THERAPY IN HEMOPHILIA A IN SOUTH OF IRAN
M. Karimi* (IR), A. Ahmadkia Daliri, K. Pourmohammadi, P. Bastani

PP-TH-535 QUALITY OF LIFE IN HEMOPHILIA COMPLICATED BY INHIBITORS
M. Karimi* (IR), K. Pourmohamadi, P. Bastani

PP-TH-536 ENHANCEMENT OF HAEMOSTATIC EFFICACY OF PLASMA-DERIVED FVIII BY FORMULATION WITH PEGYLATED LIPOSOMES
M. Baru* (IL), I. Dayan, M. Robinson

PP-TH-537 TRANSIENT ELASTOGRAPHY DISCLOSES IDENTICAL DISTRIBUTION OF LIVER FIBROSIS IN HAEMOPHILIACS WITH HCV-MONO- AND HCV/HIV-COINFECTION
N. Vidovic* (DE), R. Lochowski, F. Grünhage, G. Goldmann, B. Niemann, S. Horneff, J. Schröder, U. Spengler, T. Sauerbruch, J. Oldenburg

PP-TH-538 BONE MINERAL DENSITY IN CHILDREN WITH SEVERE HAEMOPHILIA RECEIVING REGULAR FVIII PROPHYLAXIS
N. B. Heaney, A. Gibson, S. Khanna, F. Ahmed, E. Chalmers* (UK)

PP-TH-539 ECONOMIC ASSESSMENT OF HOME TREATMENT VERSUS HOSPITAL TREATMENT WITH APCC IN INHIBITOR PATIENTS
P. A. Holme* (NO), K. Nyhus, J. Sverre, G. Tjønnfjord

PP-TH-540 DETECTION OF F8 MUTATIONS BY HIGH RESOLUTION MELTING (HRM) ANALYSIS
P. A. Bignell* (UK), D. Keeling, P. Giangrande

PP-TH-541 DETECTION OF DUPLICATIONS AND DELETIONS WITHIN THE FACTOR VIII GENE BY MPLA
P. A. Bignell* (UK), D. Keeling, P. Giangrande

PP-TH-542 INTRAMURAL URETERAL HEMORRHAGE ASSOCIATED WITH CONTRALATERAL ILIOPSOAS HEMATOMA IN A PATIENT WITH HEMOPHILIA A WITH INHIBITOR: CASE REPORT
P. R. Villaca* (BR), C. L. Dinardo, L. F. Botelho, E. P. N. Sandoval, P. L. Junqueira, E. Okazaki, A. K. Zeinad, C. S. S. S. Silva, T. R. F. Rocha, D. A. F. Chamone, E. A. D’ Amico

PP-TH-543 HEAMOPHILIA EPIDEMIOLOGY ASSESSMENT IN CENTRAL AND EAST EUROPEAN COUNTRIES PROVIDED BY ONLINE CLINICAL REGISTRY
P. Brabec* (CZ), P. Salaj, T. Pavlík

PP-TH-544 PHENOTYPE-GENOTYPE CORRELATION IN MILD HEMOPHILIA A
P. Casaña* (ES), N. Cabrera, A. R. Cid, S. Haya, A. Moret, L. Abad-Franch, J. A. Aznar

PP-TH-545 CURRENT PRACTICE IN MANAGEMENT OF MUSCLE HAEMATOMA IN PATIENTS WITH SEVERE HAEMOPHILIA
R. Beyer* (DK), J. Ingerslev, B. Sørensen

PP-TH-546 ISCHEMIC HEART DISEASE IN HAEMOPHILIAC PATIENTS
R. Santoro* (IT), S. Prejanò, P. Iannaccaro, G. Muleo

PP-TH-547 LUPUS ANTICOAGULANT IN A PATIENT WITH HAEMOPHILIA A
R. Santoro* (IT), S. Prejanò, P. Iannaccaro, G. Muleo

PP-TH-548 JOINT BLEEDING AND ARTHROPATHY EVOLUTION IN CHINESE CHILDREN HEMOPHILIAS WITHOUT ROUTINE TREATMENT AND DISCUSSION FOR CURE OPPORTUNITY
R. Wu* (CN), N. Zhang, L. Zhao, X. Wu

PP-TH-549 ASSESSMENT OF THROMBIN GENERATION IN MILD HAEMOPHILIA A WITH FACTOR VIII ASSAY DISCREPANCY
R. M. Gilmore* (IE), S. Harmon, C. Gannon, M. Byrne, B. White, J. S. O’Donnell, P. V. Jenkins

PP-TH-550 MALIGNANT GONADAL GERM CELL TUMOR WITH PARANEOPLASTIC PULMONARY EMBOLISM IN A PATIENT WITH SEVERE HEMOPHILIA A
S. Struve* (DE), M. Griesshammer

PP-TH-551 DIFFERENT ONE STAGE FVIII ACTIVITY RESULTS IN A PATIENT WITH MODERATE HAEMOPHILIA A DEPENDING ON THE TYPE OF APTT REAGENT USED
S. V. Brooks* (UK), S. Aghighi, K. Gomez, G. Mellars, M. Mathias

PP-TH-552 URINARY EXCRETION OF 8-ISO-PGF2 IN HEMOPHILIA A PATIENTS WITH OR WITHOUT INHIBITOR DURING ACUTE JOINT BLEEDING, AND STATE OF FACTOR THERAPY
S. Cheng* (TW), C. Yc

PP-TH-553 DETECTION OF 101 NOVEL MUTATIONS IN THE FACTOR 8 GENE OF IRANIANS HEMOPHILIA A PATIENTS
S. Ravanbod* (IR), G. Rastegarlari, M. Rassoulzadegan, F. Ala, S. Enayat

PP-TH-554 SCREENING LABORATORY BRAZILIAN PROGRAM OF HAEMOPHILIA AND INHIBITORS
S. A. L. Montalvão* (BR), E. V. de Paula, S. Thomas, J. M. Annichino-Bizzacchi, M. C. Ozelo

PP-TH-555 FACTOR VIII GENE MUTATIONS IN PATIENTS WITH SEVERE HEMOPHILIA A AND INHIBITORS FROM VENEZUELA
S. Albanez* (VE), N. de Bosch, A. Boadas, A. Sáez, A. Porco

PP-TH-556 ABERRANT DIAGNOSTIC PATTERN IN A BRAZILIAN PATIENT WITH SEVERE HEMOPHILIA A EXPLAINABLE BY AN INT1H-RELATED INVERSION COMBINED WITH A DELETION IN F8
C. Mühle, S. F. Pio, D. Zouain, G. Correa, S. M. Rezende* (BR)

PP-TH-557 LOW-DOSE THROMBOPROPHYLAXIS IN A HEMOPHILIC PATIENT UNDERGOING HIP SURGERY
S. Stankovic* (MK), A. Stojanovic, T. Smilevska, Z. Stojanovski, T. Sotirova, S. Trajkova, A. Ljatifi, D. Dukovski, L. Cevreska

PP-TH-558 HEALTH-RELATED QUALITY OF LIFE IN ELDERLY HAEMOPHILIA PATIENTS
S. von Mackensen* (DE), A. Gringeri, S. Siboni, M. Ferretti, F. Tradati, M. Franchini, A. Tagliaferri, E. Santagostino, P. Mannucci

PP-TH-559 A HAEMOPHILIA-SPECIFIC AQUA-TRAINING FOR HAEMOPHILIA PATIENTS – RESULTS OF THE WATERCISE - QUALITY OF LIFE STUDY (WAT-QOL)
S. von Mackensen* (DE), A. Wieloch, D. Zäch, B. Eifrig, J. Kalnins, W. Zeller

PP-TH-560 IMPACT OF HAEMOPHILIA EDUCATION ON PATIENTS AND FAMILIES IN A DEVELOPING COUNTRY
T. Zafar* (PK)

PP-TH-561 PROLONGED HALF-LIFE OF RECOMBINANT FACTOR VIIa FUSION PROTEIN - SINGLE DOSE STUDY IN RABBITS
U. Kronthaler* (DE), S. Schmidbauer, U. Liebing, W. Lang, H. J. Metzner, T. Weimer, S. Schulte

PP-TH-562 PREVALENCE OF THE FACTOR VIII GENE INTRON 1 INVERSION IN CHINESE HAEMOPHILIAC AND ITS APPLICATION TO THE CARRIER DETECTION AND PRENATAL DIAGNOSIS
Y. Lu* (CN), X. Wang, Q. Ding, J. Dai, X. Xi, H. Wang

PP-TH-563 HAEMOPHILIA A IN A FEMALE WITH DE NOVEL INV22 AND SKEWED XCHROMOSOME INACTIVA